The NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic. Scientists within and supported by the NCI have made a number of key discoveries. HIV/AIDS research is conducted throughout the Divisions and Offices of the NCI and is coordinated by the NCI Office of HIV and AIDS Malignancy.
-In addition, because HIV/AIDS transcends every area of clinical medicine and basic scientific investigation, the NIH AIDS research effort involves every NIH Institute and Center. The NIH Office of AIDS Research has primary responsibility for planning and coordinating AIDS research across the NIH.
- ++ NCI has played a major role in HIV/AIDS research since the beginning of the + AIDS epidemic. Scientists within NCI, as well as those supported by NCI, have + made a number of key discoveries. HIV/AIDS research is conducted throughout + the divisions and offices of NCI and is coordinated by the NCI Office of HIV and AIDS Malignancy. +
++ In addition, because HIV/AIDS transcends every area of clinical medicine and + basic scientific investigation, the NIH AIDS research effort involves every + NIH Institute and Center. The NIH Office of AIDS Research has primary + responsibility for planning and coordinating AIDS research across NIH. +
+ +This graph displays a historical view of the Professional Judgment Budget, the President's Budget, and the Enacted Appropriations for the NCI from fiscal years 1974 through 2023. The National Cancer Act gives the NCI Director special authority to submit an annual Professional Judgment Budget, sometimes referred to as the "Bypass Budget," directly to the President and Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. The President's Budget is an annual report prepared by the White House, and in coordination with federal agencies, proposing funding levels for the federal government, including for the NIH and NCI, according to the President's priorities. Congress reviews the Professional Judgment Budget and the President's Budget, and then conducts its own inquiries and hearings to develop and pass an appropriations bill to fund the government. When the bill is signed into law by the President, the Enacted Appropriation levels become available for NCI's cancer research activities.
- ++ This graph displays a historical view of the Professional Judgment Budget, the + President's Budget, and the Enacted Appropriations for the NCI from fiscal + years 1974 through 2026. The National Cancer Act gives the NCI Director + special authority to submit an annual Professional Judgment Budget, sometimes + referred to as the "Bypass Budget," directly to the President and Congress. + This budget reflects NCI cancer research priorities and identifies areas of + potential investment in cancer research. The President's Budget is an annual + report prepared by the White House, in coordination with federal agencies. It + proposes funding levels for the federal government, including for the NIH and + NCI, according to the President's priorities. Congress reviews the + Professional Judgment Budget and the President's Budget, and then conducts its + own inquiries and hearings to develop and pass an appropriations bill to fund + the government. When the bill is signed into law by the President, the Enacted + Appropriation levels become available for NCI's cancer research activities. +
+ +| FY | ++ Professional Judgement Budget* + | ++ President's Budget* + | ++ Enacted Appropriation* + | +
|---|---|---|---|
| 1974 | +$640,031 | +$500,000 | +$551,192 | +
| 1975 | +$750,000 | +$600,000 | +$691,666 | +
| 1976 | +$898,500 | +$605,000 | +$914,628 | +
| 1977 | +$948,000 | +$687,670 | +$815,000 | +
| 1978 | +$955,000 | +$818,936 | +$872,388 | +
| 1979 | +$1,036,000 | +$878,802 | +$937,129 | +
| 1980 | +$1,055,000 | +$936,958 | +$1,000,000 | +
| 1981 | +$1,170,000 | +$1,007,800 | +$989,355 | +
| 1982 | +$1,192,000 | +$1,025,946 | +$986,617 | +
| 1983 | +$1,197,000 | +$955,449 | +$987,642 | +
| 1984 | +$1,074,000 | +$986,681 | +$1,081,581 | +
| 1985 | +$1,189,000 | +$916,485 | +$1,183,806 | +
| 1986 | +$1,460,000 | +$1,126,012 | +$1,264,159 | +
| 1987 | +$1,570,000 | +$1,158,089 | +$1,402,837 | +
| 1988 | +$1,700,000 | +$1,302,823 | +$1,469,327 | +
| 1989 | +$2,080,000 | +$1,468,256 | +$1,593,536 | +
| 1990 | +$2,195,000 | +$1,494,741 | +$1,664,000 | +
| 1991 | +$2,410,000 | +$1,694,059 | +$1,766,324 | +
| 1992 | +$2,612,000 | +$1,810,230 | +$1,989,278 | +
| 1993 | +$2,775,000 | +$2,010,439 | +$2,007,483 | +
| 1994 | +$3,200,000 | +$2,142,122 | +$2,082,267 | +
| 1995 | +$3,600,000 | +$1,967,709 | +$2,135,119 | +
| 1996 | +$3,640,000 | +$1,994,007 | +$2,251,084 | +
| 1997 | +$2,977,000 | +$2,060,392 | +$2,382,532 | +
| 1998 | +$2,702,500 | +$2,217,482 | +$2,547,314 | +
| 1999 | +$3,191,000 | +$2,528,760 | +$2,927,187 | +
| 2000 | +$3,873,000 | +$2,732,795 | +$3,332,317 | +
| 2001 | +$4,135,000 | +$3,249,730 | +$3,757,242 | +
| 2002 | +$5,030,000 | +$4,177,203 | +$4,190,405 | +
| 2003 | +$5,690,000 | +$4,673,510 | +$4,622,394 | +
| 2004 | +$5,986,000 | +$4,770,519 | +$4,770,519 | +
| 2005 | +$6,211,000 | +$4,870,025 | +$4,865,525 | +
| 2006 | +$6,170,000 | +$4,841,774 | +$4,841,774 | +
| 2007 | +$5,949,714 | +$4,753,609 | +$4,797,639 | +
| 2008 | +$5,865,788 | +$4,782,114 | +$4,890,525 | +
| 2009 | +$6,028,386 | +$4,809,819 | +$4,968,973 | +
| 2010 | +$7,193,393 | +$5,150,170 | +$5,103,388 | +
| 2011 | +$6,199,666 | +$5,264,643 | +$5,103,388 | +
| 2012 | +$5,869,857 | +$5,196,136 | +$5,081,788 | +
| 2013 | +$5,833,010 | +$5,068,864 | +$5,072,183 | +
| 2014 | ++ | $5,125,951 | +$4,923,238 | +
| 2015 | ++ | $4,930,715 | +$4,950,396 | +
| 2016 | +$5,754,000 | +$5,098,479 | +$5,214,701 | +
| 2017 | +$5,453,000 | +$5,893,509 | +$5,689,329 | +
| 2018 | ++ | $4,474,222 | +$5,964,800 | +
| 2019 | +$6,380,000 | +$5,626,312 | +$6,143,892 | +
| 2020 | +$6,522,000 | +$5,246,737 | +$6,440,442 | +
| 2021 | +$6,928,000 | +$5,881,173 | +$6,559,852 | +
| 2022 | +$7,609,000 | +$6,733,302 | +$6,912,522 | +
| 2023 | +$7,766,000 | +$6,713,851 | +$7,320,159 | +
| 2024 | +$9,988,000 | +$7,820,159 | +$7,224,159 | +
| 2025 | +$11,466,000 | +$7,839,141 | +$7,224,159 | +
| 2026 | +$11,466,000 | ++ | + |
NCI receives its budget from the United States Congress as part of the federal budget process for the Department of Health and Human Services and NIH.
-The NCI budget for FY 2021 (October 1, 2020 through September 30, 2021) is $6.56 billion. During the period from 2010 through 2021, the NCI budget averaged $5.52 billion per year.
- - -| Fiscal Years | -Amount | -Notes | -|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1938 - 2002 | -$52,940,982,220 | -- | |||||||||||
| 2003 | -4,622,394,000 | -Prior to reductions in PL 108-7(-$30,046,000 for the enacted rescission and $2,000 lapse). Includes $263,442,000 of AIDS funding. | -|||||||||||
| 2004 | -4,770,519,000 | -Prior to reductions in PL 108-199(-$3,136,000 for Labor/HHS/ED rescission; $28,128,000 for across the board reduction; -$15,357,000 NIH 1% transfer assessment, and $5,000 lapse). Includes $266,975,000 of AIDS funding. | -|||||||||||
| 2005 | -4,865,525,000 | -Prior to reductions in PL 108-447($38,914,000 .8% across the board reduction; -$1,353,000 for Labor/HHS/ED rescission; -$30,505,000 NIH 1% transfer assessment, and $9,000 lapse). Includes $265,907,000 of AIDS funding. | -|||||||||||
| 2006 | -4,841,774,000 | -Prior to reductions in PL 109-149 (-$48,418,000 for Labor/HHS/ED rescission; -$3,293,000 HHS transfer for CMS activities; -$42,834,000 NIH 1% transfer for roadmap activities, and $4,000 lapse). Includes $253,866,000 of AIDS funding. | -|||||||||||
| 2007 | -4,797,639,000 | -Prior to reductions in PL 110-5 (-$5,015,000 NIH transfer for GEI activities, and $9,000 lapse). Includes $253,866,000 of AIDS funding. | -|||||||||||
| 2008 | -4,890,525,000 | -Prior to -$85,437,000 rescission and $3,091,000 in NIH transfer activities. Includes supplemental appropriation of $25,559,000. Includes $258,499,000 of AIDS funding. | -|||||||||||
| 2009 | -4,968,973,000 | -Prior to reductions in PL 111-8 (-$2,042,631 NIH transfer for activities, and $4,000 lapse). Includes $265,882,000 of AIDS funding. | -|||||||||||
| 2010 | -5,103,388,000 | -Prior to -$760,000 HHS Secretary's transfer, -$4,459,000 in NIH transfer for activities, and $22,000 lapse. Includes $272,130,000 of AIDS funding. | -|||||||||||
| 2011 | -5,103,388,000 | -Prior to -$44,810,787 recission and $472,000 lapse. Includes $269,953,000 of AIDS funding. | -|||||||||||
| 2012 | -5,081,788,000 | -Prior to $9,605,579 rescission, -$1,445,000 HHS Secretary's transfer ,-$3,342,000 HHS Secretary's transfer for Alzheimer's research, and $54,000 lapse. Includes $271,692,000 of AIDS funding. | -|||||||||||
| 2013 | -5,072,183,000 | -Prior to -$254,589,000 under sequestration (Budget Control Act, 2011, PL 112–25), -$10,144,367 recission, -$28,044,000 HHS Secretary's transfer and +$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and $106,000 lapse. Includes $261,550,000 of AIDS funding. | -|||||||||||
| 2014 | -4,923,238,000 | -Prior to -$12,359,000 HHS Secretary's transfer,-$965,000 HHS Secretary’s Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), +$16,180,552 transfer from National Children's Study, and +$6,307,000 transfer from NIH Office of AIDS Research, and $33,000 lapse. Includes $269,212,000 of AIDS funding. | -|||||||||||
| 2015 | -4,950,396,000 | -Prior to +$2,632,000 transfer from NIH Office of AIDS Research and $435,000 lapse. Includes $269,660,000 of AIDS funding. | -|||||||||||
| 2016 | -5,214,701,000 | -Prior to -$7,217,390 HHS Secretary's transfer, -$1,192,000 transfer to NIH Office of AIDS Research, and $122,000 lapse. Includes $266,422,000 of AIDS funding. | -|||||||||||
| 2017 | -5,689,329,000 | -Prior to -$11,971,000 HHS Secretary's transfer, -$17,403,000 transfer to NIH Office of AIDS Research, and $247,000 lapse. Includes $249,019,000 of AIDS funding and $300,000,000 of Cancer Moonshot℠ funding. | -|||||||||||
| 2018 | -5,964,800,000 | -Prior to -$13,309,000 HHS Secretary's transfer, -$7,785,000 transfer to NIH Office of AIDS Research, and $250,000 lapse. Includes $241,234,000 of AIDS funding and $300,000,000 of Cancer Moonshot℠ funding. | -|||||||||||
| 2019 | -6,143,892,000 | -Prior to -$19,730,000 HHS Secretary's transfer, -$2,874,000 transfer to NIH Office of AIDS Research, and $252,786 lapse. Includes $241,979,000 of AIDS funding and $400,000,000 of Cancer Moonshot℠ funding. | -|||||||||||
| 2020 | -6,440,442,000 | -
- Prior to -$4,000 transfer to NIH Office of AIDS Research, and $254,618 lapse. Includes $241,975,000 of AIDS funding and $195,000,000 of Cancer Moonshot℠ funding. - |
- |||||||||||
| 2021 | -6,559,852,000 | -
- Prior to -$1,047,000 transfer to NIH Office of AIDS Research, Secretary's Transfer -$19,109,000, and $289,223 lapse. Includes $240,513,000 of AIDS funding, and $195,000,000 of Cancer Moonshot℠ funding. - |
- |||||||||||
| 1938 - 2021 | -$152,945,728,220 | -- | |||||||||||
| + Fiscal Years + | ++ Amount + | ++ Notes + | +
|---|---|---|
| + 1938 - 2002 + | ++ $52,940,982,220 + | ++ |
| + 2003 + | ++ $4,622,394,000 + | ++ Prior to reductions in PL 108-7(-$30,046,000 for the enacted rescission + and $2,000 lapse). Includes $263,442,000 of AIDS funding. + | +
| + 2004 + | ++ $4,770,519,000 + | ++ Prior to reductions in PL 108-199(-$3,136,000 for Labor/HHS/ED + rescission; $28,128,000 for across the board reduction; -$15,357,000 NIH + 1% transfer assessment, and $5,000 lapse). Includes $266,975,000 of AIDS + funding. + | +
| + 2005 + | ++ $4,865,525,000 + | ++ Prior to reductions in PL 108-447($38,914,000 .8% across the board + reduction; -$1,353,000 for Labor/HHS/ED rescission; -$30,505,000 NIH 1% + transfer assessment, and $9,000 lapse). Includes $265,907,000 of AIDS + funding. + | +
| + 2006 + | ++ $4,841,774,000 + | ++ Prior to reductions in PL 109-149 (-$48,418,000 for Labor/HHS/ED + rescission; -$3,293,000 HHS transfer for CMS activities; -$42,834,000 + NIH 1% transfer for roadmap activities, and $4,000 lapse). Includes + $253,866,000 of AIDS funding. + | +
| + 2007 + | ++ $4,797,639,000 + | ++ Prior to reductions in PL 110-5 (-$5,015,000 NIH transfer for GEI + activities, and $9,000 lapse). Includes $253,866,000 of AIDS funding. + | +
| + 2008 + | ++ $4,890,525,000 + | ++ Prior to -$85,437,000 rescission and $3,091,000 in NIH transfer + activities. Includes supplemental appropriation of $25,559,000. Includes + $258,499,000 of AIDS funding. + | +
| + 2009 + | ++ $4,968,973,000 + | ++ Prior to reductions in PL 111-8 (-$2,042,631 NIH transfer for + activities, and $4,000 lapse). Includes $265,882,000 of AIDS funding. + | +
| + 2010 + | ++ $5,103,388,000 + | ++ Prior to -$760,000 HHS Secretary's transfer, -$4,459,000 in NIH transfer + for activities, and $22,000 lapse. Includes $272,130,000 of AIDS + funding. + | +
| + 2011 + | ++ $5,103,388,000 + | ++ Prior to -$44,810,787 recission and $472,000 lapse. Includes + $269,953,000 of AIDS funding. + | +
| + 2012 + | ++ $5,081,788,000 + | ++ Prior to $9,605,579 rescission, -$1,445,000 HHS Secretary's transfer + ,-$3,342,000 HHS Secretary's transfer for Alzheimer's research, and + $54,000 lapse. Includes $271,692,000 of AIDS funding. + | +
| + 2013 + | ++ $5,072,183,000 + | ++ Prior to -$254,589,000 under sequestration (Budget Control Act, 2011, PL + 112–25), -$10,144,367 recission, -$28,044,000 HHS Secretary's transfer + and +$9,714,000 restored from the National Children's Study and National + Eye Institute HIV/AIDS funding, and $106,000 lapse. Includes + $261,550,000 of AIDS funding. + | +
| + 2014 + | ++ $4,923,238,000 + | ++ Prior to -$12,359,000 HHS Secretary's transfer,-$965,000 HHS Secretary’s + Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), + +$16,180,552 transfer from National Children's Study, and +$6,307,000 + transfer from NIH Office of AIDS Research, and $33,000 lapse. Includes + $269,212,000 of AIDS funding. + | +
| + 2015 + | ++ $4,950,396,000 + | ++ Prior to +$2,632,000 transfer from NIH Office of AIDS Research and + $435,000 lapse. Includes $269,660,000 of AIDS funding. + | +
| + 2016 + | ++ $5,214,701,000 + | ++ Prior to -$7,217,390 HHS Secretary's transfer, -$1,192,000 transfer to + NIH Office of AIDS Research, and $122,000 lapse. Includes $266,422,000 + of AIDS funding. + | +
| + 2017 + | ++ $5,689,329,000 + | ++ Prior to -$11,971,000 HHS Secretary's transfer, -$17,403,000 transfer to + NIH Office of AIDS Research, and $247,000 lapse. Includes $249,019,000 + of AIDS funding and $300,000,000 of Cancer Moonshot℠ funding. + | +
| + 2018 + | ++ $5,964,800,000 + | ++ Prior to -$13,309,000 HHS Secretary's transfer, -$7,785,000 transfer to + NIH Office of AIDS Research, and $250,000 lapse. Includes $241,234,000 + of AIDS funding and $300,000,000 of Cancer Moonshot℠ funding. + | +
| + 2019 + | ++ $6,143,892,000 + | ++ Prior to -$19,730,000 HHS Secretary's transfer, -$2,874,000 transfer to + NIH Office of AIDS Research, and $252,786 lapse. Includes $241,979,000 + of AIDS funding and $400,000,000 of Cancer Moonshot℠ funding. + | +
| + 2020 + | ++ $6,440,442,000 + | ++ Prior to -$4,000 transfer to NIH Office of AIDS Research, and $254,618 + lapse. Includes $241,975,000 of AIDS funding and $195,000,000 of Cancer + Moonshot℠ funding. + | +
| + 2021 + | ++ $6,559,852,000 + | ++ Prior to -$1,047,000 transfer to NIH Office of AIDS Research, + Secretary's Transfer -$19,109,000, and $289,223 lapse. Includes + $240,513,000 of AIDS funding, and $195,000,000 of Cancer Moonshot℠ + funding. + | +
| + 2022 + | ++ $6,912,522,000 + | ++ Prior to -$2,896,000 transfer to NIH Office of AIDS Research, + Secretary's Transfer -$0, and $248,297 lapse. Includes $248,940,000 of + AIDS funding, and $194,000,000 of Cancer Moonshot℠ funding. + | +
| + 2023 + | ++ $7,320,159,000 + | ++ Prior to -$2,918,000 transfer to NIH Office of AIDS Research, and + $234,418 lapse. Includes $256,734,000 of AIDS funding, and $216,000,000 + of Cancer Moonshot℠ funding. + | +
| + 2024 + | ++ $7,224,159,000 + | ++ Prior to -$2,918,000 transfer to NIH Office of AIDS Research, and + $324,597 lapse. Includes $256,734,000 of AIDS funding. + | +
| + 1938 - 2024 + | ++ $174,402,568,220 + | ++ |
+ This page displays the number and dollar amount of grant and contract awards + by state and country, with details for institutions receiving more than $15 + million in support from NCI. +
++ Grants are used when no substantial programmatic involvement + is anticipated between NCI and the grant recipient during performance of the + financially assisted activities. They are also used when there is no + expectation on the part of NCI of a specified service or product for + NCI. +
++ Contracts are used to procure cancer research services and + other resources that the federal government needs to advance the NCI cancer + research mission. +
++ Moving forward, all NCI obligations related to grants and contract awards will + be included for each fiscal year. According to the National Institutes of + Health’s Office of Extramural Research, the "Count Rules" and associated + policy guidelines are updated annually, with funding limits determined by cost + center and division. A value of “0” indicates an award that is funded by + another NIH Institute but is co-funded by the NCI. +
field_site_section: - '#process': callback: 'reference' @@ -306,756 +1294,839 @@ computed_path: '/about-nci/budget/fact-book/extramural-programs/grant-contract-awards' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' + field_body_section_heading: + value: 'Grant and Contract Awards by State and Institution' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -The following displays the number and dollar amount of grant and contract awards by state and country with details for institutions receiving more than $15 million in support from NCI.
-Grants are used when no substantial programmatic involvement is anticipated between the NCI and the grant recipient during performance of the financially assisted activities and when there is no expectation on the part of the NCI of a specified service or product for NCI.
-Contracts are used to procure cancer research services and other resources that the Federal government needs to advance the NCI cancer research mission.
-Grant and contract data includes FY 2021 Cancer Moonshot funds and excludes FYs 2017 through 2020 Cancer Moonshot carryover obligations, Breast Cancer Stamp, NRSA tap, the Loan Repayment Program, Program Evaluation, and other assessments. Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.
-In the map graphic below, grant and contract awards are presented by state. The table below the graphic provides information for U.S. territories. Within each state, hover to view the total amount awarded and click to view detailed data on institutions that received more than $15 million in support from NCI during FY 2021. For purposes of the Fact Book, institutions include universities, cancer centers, and hospitals.
-Other category represents total grant and contract funding in that state for all remaining organizations including universities, cancer centers, and hospitals who receive less than $15 million in NCI support.
+ ++ In the map graphic below, grant and contract awards are presented by state. + The table below the graphic provides information for U.S. territories. Within + each state on the graphic, hover to view the total amount awarded and click to + view detailed data on institutions that received more than $15 million in + support from NCI during fiscal year 2024. For purposes of the NCI Budget Fact + Book, institutions include universities, cancer centers, and hospitals. +
+| State | -No. of Grants | -Amount for Grants | -No. of Contracts | -Amount for Contracts | -Total Number | -Total Amount | +
|---|---|---|---|---|---|---|
| State | ++ No. of Grants + | ++ Amount for Grants + | ++ No. of Contracts + | ++ Amount for Contracts + | +Total Number | +Total Amount |
| Alabama | -67 | -$36,714,200 | -2 | -$609,176 | -69 | -$37,323,376 | -
| Alaska | -1 | -$784,322 | -0 | -$0 | -1 | -$784,322 | -
| Arizona | -56 | -$40,139,491 | -2 | -$345,067 | -58 | -$40,484,558 | -
| Arkansas | -22 | -$7,633,357 | -2 | -$56,000 | -24 | -$7,689,357 | -
| California | -970 | -$594,687,856 | -20 | -$23,757,753 | -990 | -$618,445,609 | -
| Colorado | -98 | -$37,769,184 | -1 | -$1,000 | -99 | -$37,770,184 | -
| Connecticut | -124 | -$57,681,665 | -2 | -$3,170,248 | -126 | -$60,851,913 | -
| Delaware | -6 | -$5,157,832 | -0 | -$0 | -6 | -$5,157,832 | -
| Dist Of Col | -69 | -$34,215,156 | -9 | -$3,294,378 | -78 | -$37,509,534 | -
| Florida | -200 | -$92,259,734 | -4 | -$2,465,477 | -204 | -$94,725,211 | -
| Georgia | -122 | -$55,011,549 | -5 | -$5,284,513 | -127 | -$60,296,062 | -
| Hawaii | -17 | -$14,729,016 | -1 | -$1,557,557 | -18 | -$16,286,573 | -
| Idaho | -0 | -$0 | -1 | -$521,188 | -1 | -$521,188 | -
| Illinois | -250 | -$136,009,783 | -12 | -$7,626,037 | -262 | -$143,635,820 | -
| Indiana | -82 | -$36,646,382 | -1 | -$136,666 | -83 | -$36,783,048 | -
| Iowa | -34 | -$22,562,761 | -1 | -$4,162,658 | -35 | -$26,725,419 | -
| Kansas | -15 | -$9,743,738 | -0 | -$0 | -15 | -$9,743,738 | -
| Kentucky | -54 | -$22,427,109 | -2 | -$2,723,444 | -56 | -$25,150,553 | -
| Louisiana | -28 | -$10,763,030 | -1 | -$1,772,202 | -29 | -$12,535,232 | -
| Maine | -20 | -$11,845,729 | -0 | -$0 | -20 | -$11,845,729 | -
| Maryland | -192 | -$97,619,193 | -46 | -$518,828,181 | -238 | -$616,447,374 | -
| Massachusetts | -725 | -$406,169,072 | -6 | -$5,940,126 | -731 | -$412,109,198 | -
| Michigan | -205 | -$105,536,540 | -3 | -$53,087 | -208 | -$105,589,627 | -
| Minnesota | -164 | -$98,740,990 | -7 | -$1,575,739 | -171 | -$100,316,729 | -
| Mississippi | -1 | -$397,445 | -0 | -$0 | -1 | -$397,445 | -
| Missouri | -138 | -$76,735,643 | -4 | -$4,391,995 | -142 | -$81,127,638 | -
| Montana | -3 | -$1,388,885 | -0 | -$0 | -3 | -$1,388,885 | -
| Nebraska | -43 | -$20,863,288 | -0 | -$0 | -43 | -$20,863,288 | -
| Nevada | -3 | -$2,259,468 | -0 | -$0 | -3 | -$2,259,468 | -
| New Hampshire | -34 | -$17,839,375 | -2 | -$56,000 | -36 | -$17,895,375 | -
| New Jersey | -78 | -$40,776,237 | -4 | -$11,212,602 | -82 | -$51,988,839 | -
| New Mexico | -19 | -$13,076,176 | -1 | -$2,649,530 | -20 | -$15,725,706 | -
| New York | -852 | -$478,732,591 | -6 | -$9,243,747 | -858 | -$487,976,338 | -
| North Carolina | -271 | -$139,901,504 | -5 | -$1,615,708 | -276 | -$141,517,212 | -
| Ohio | -258 | -$129,653,558 | -5 | -$1,433,807 | -263 | -$131,087,365 | -
| Oklahoma | -34 | -$16,255,858 | -2 | -$2,289,369 | -36 | -$18,545,227 | -
| Oregon | -82 | -$57,231,938 | -1 | -$1,000 | -83 | -$57,232,938 | -
| Pennsylvania | -467 | -$270,163,068 | -4 | -$366,422 | -471 | -$270,529,490 | -
| Rhode Island | -17 | -$6,553,180 | -0 | -$0 | -17 | -$6,553,180 | -
| South Carolina | -62 | -$34,396,472 | -0 | -$0 | -62 | -$34,396,472 | -
| South Dakota | -3 | -$1,416,538 | -0 | -$0 | -3 | -$1,416,538 | -
| Tennessee | -183 | -$108,001,670 | -5 | -$3,958,571 | -188 | -$111,960,241 | -
| Texas | -559 | -$275,706,465 | -4 | -$4,723,822 | -563 | -$280,430,287 | -
| Utah | -81 | -$32,501,856 | -2 | -$2,585,808 | -83 | -$35,087,664 | -
| Vermont | -9 | -$6,303,528 | -2 | -$419,715 | -11 | -$6,723,243 | -
| Virginia | -95 | -$53,081,747 | -20 | -$50,676,441 | -115 | -$103,758,188 | -
| Washington | -219 | -$152,470,779 | -5 | -$6,209,625 | -224 | -$158,680,404 | -
| West Virginia | -6 | -$1,386,871 | -0 | -$0 | -6 | -$1,386,871 | -
| Wisconsin | -106 | -$71,302,138 | -3 | -$1,611,525 | -109 | -$72,913,663 | -
| Wyoming | -1 | -$186,018 | -0 | -$0 | -1 | -$186,018 | +
| Alabama | +80 | +$38,267,179 | +0 | +$0 | +80 | +$38,267,179 | +
| Alaska | +2 | +$1,194,564 | +0 | +$0 | +2 | +$1,194,564 | +
| Arizona | +62 | +$36,186,273 | +0 | +$0 | +62 | +$36,186,273 | +
| Arkansas | +21 | +$7,027,667 | +0 | +$0 | +21 | +$7,027,667 | +
| California | +978 | +$614,150,097 | +0 | +$0 | +978 | +$614,150,097 | +
| Colorado | +94 | +$42,965,447 | +0 | +$0 | +94 | +$42,965,447 | +
| Connecticut | +137 | +$63,725,309 | +0 | +$0 | +137 | +$63,725,309 | +
| Delaware | +9 | +$5,082,317 | +0 | +$0 | +9 | +$5,082,317 | +
| Dist Of Col | +69 | +$36,537,335 | +0 | +$0 | +69 | +$36,537,335 | +
| Florida | +222 | +$111,933,853 | +0 | +$0 | +222 | +$111,933,853 | +
| Georgia | +135 | +$68,540,930 | +0 | +$0 | +135 | +$68,540,930 | +
| Hawaii | +20 | +$18,118,336 | +0 | +$0 | +20 | +$18,118,336 | +
| Idaho | +1 | +$424,500 | +0 | +$0 | +1 | +$424,500 | +
| Illinois | +259 | +$148,845,532 | +0 | +$0 | +259 | +$148,845,532 | +
| Indiana | +81 | +$41,983,040 | +0 | +$0 | +81 | +$41,983,040 | +
| Iowa | +31 | +$16,474,412 | +0 | +$0 | +31 | +$16,474,412 | +
| Kansas | +28 | +$13,867,899 | +0 | +$0 | +28 | +$13,867,899 | +
| Kentucky | +49 | +$21,556,044 | +0 | +$0 | +49 | +$21,556,044 | +
| Louisiana | +28 | +$13,968,695 | +0 | +$0 | +28 | +$13,968,695 | +
| Maine | +15 | +$9,536,624 | +0 | +$0 | +15 | +$9,536,624 | +
| Maryland | +218 | +$114,173,711 | +0 | +$0 | +218 | +$114,173,711 | +
| Massachusetts | +661 | +$384,428,561 | +0 | +$0 | +661 | +$384,428,561 | +
| Michigan | +220 | +$111,646,183 | +0 | +$0 | +220 | +$111,646,183 | +
| Minnesota | +181 | +$115,286,954 | +0 | +$0 | +181 | +$115,286,954 | +
| Mississippi | +2 | +$603,338 | +0 | +$0 | +2 | +$603,338 | +
| Missouri | +173 | +$91,631,809 | +0 | +$0 | +173 | +$91,631,809 | +
| Montana | +4 | +$2,153,715 | +0 | +$0 | +4 | +$2,153,715 | +
| Nebraska | +42 | +$17,323,908 | +0 | +$0 | +42 | +$17,323,908 | +
| Nevada | +4 | +$2,285,893 | +0 | +$0 | +4 | +$2,285,893 | +
| New Hampshire | +34 | +$18,538,972 | +0 | +$0 | +34 | +$18,538,972 | +
| New Jersey | +80 | +$40,963,723 | +0 | +$0 | +80 | +$40,963,723 | +
| New Mexico | +16 | +$9,941,462 | +0 | +$0 | +16 | +$9,941,462 | +
| New York | +936 | +$534,116,973 | +0 | +$0 | +936 | +$534,116,973 | +
| North Carolina | +308 | +$152,375,497 | +0 | +$0 | +308 | +$152,375,497 | +
| Ohio | +273 | +$146,258,353 | +0 | +$0 | +273 | +$146,258,353 | +
| Oklahoma | +31 | +$16,216,171 | +0 | +$0 | +31 | +$16,216,171 | +
| Oregon | +84 | +$55,634,371 | +0 | +$0 | +84 | +$55,634,371 | +
| Pennsylvania | +459 | +$300,932,229 | +0 | +$0 | +459 | +$300,932,229 | +
| Rhode Island | +19 | +$6,491,464 | +0 | +$0 | +19 | +$6,491,464 | +
| South Carolina | +68 | +$35,541,934 | +0 | +$0 | +68 | +$35,541,934 | +
| South Dakota | +3 | +$1,531,804 | +0 | +$0 | +3 | +$1,531,804 | +
| Tennessee | +189 | +$116,601,953 | +0 | +$0 | +189 | +$116,601,953 | +
| Texas | +664 | +$338,841,966 | +0 | +$0 | +664 | +$338,841,966 | +
| Utah | +79 | +$37,343,518 | +0 | +$0 | +79 | +$37,343,518 | +
| Vermont | +13 | +$7,959,644 | +0 | +$0 | +13 | +$7,959,644 | +
| Virginia | +124 | +$78,221,223 | +0 | +$0 | +124 | +$78,221,223 | +
| Washington | +229 | +$163,050,492 | +0 | +$0 | +229 | +$163,050,492 | +
| West Virginia | +7 | +$2,252,337 | +0 | +$0 | +7 | +$2,252,337 | +
| Wisconsin | +116 | +$77,933,851 | +0 | +$0 | +116 | +$77,933,851 | +
| + Subtotal + | ++ 7,558 + | ++ $4,290,668,062 + | ++ 0 + | ++ $0 + | ++ 7,558 + | ++ $4,290,668,062 + | +
| Guam | +1 | +$1,318,336 | +0 | +$0 | +1 | +$1,318,336 | +
| Puerto Rico | +8 | +$4,372,748 | +0 | +$0 | +8 | +$4,372,748 | +
| + Total + | ++ 7,567 + | ++ $4,296,359,146 + | ++ 0 + | ++ $0 + | ++ 7,567 + | ++ $4,296,359,146 + |
| Country | -No. of Grants | -Amount for Grants | -No. of Contracts | -Amount for Contracts | -Total Number | -Total Amount | -
|---|---|---|---|---|---|---|
| Guam | -1 | -$1,422,643 | -0 | -$0 | -1 | -$1,532,165 | -
| Puerto Rico | -7 | -$5,657,267 | -0 | -$0 | -7 | -$5,929,207 | -
NCI funds and co-funds cancer research all over the world. The table below lists number and dollar amount of grant and contract awards by country.
- -| Country | -No. of Grants | -Amount for Grants | -No. of Contracts | -Amount for Contracts | -Total Number | -Total Amount | +|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Country | +No. of Grants | +Amount for Grants | +No. of Contracts | +Amount for Contracts | +Total Number | +Total Amount | |||||||
| Argentina | -1 | -$155,024 | -0 | -$0 | -1 | -$155,024 | -|||||||
| Australia | -4 | -2,837,312 | -0 | -0 | -4 | -2,837,312 | -|||||||
| Belarus | -0 | -0 | -1 | -153,832 | -1 | -153,832 | -|||||||
| Canada | -11 | -6,648,386 | -0 | -0 | -11 | -6,648,386 | -|||||||
| Costa Rica | -0 | -0 | -1 | -835,869 | -1 | -835,869 | -|||||||
| Denmark | -1 | -406,906 | -0 | -0 | -1 | -406,906 | -|||||||
| France | -6 | -4,283,732 | -0 | -0 | -6 | -4,283,732 | -|||||||
| Germany | -1 | -1,032,409 | -0 | -0 | -1 | -1,032,409 | -|||||||
| Jamaica | -0 | -50,000 | -0 | -0 | -0 | -50,000 | -|||||||
| Nigeria | -0 | -170,447 | -0 | -0 | -0 | -170,447 | -|||||||
| South Africa | -3 | -595,566 | -0 | -0 | -3 | -595,566 | -|||||||
| Sweden | -2 | -415,814 | -0 | -0 | -2 | -415,814 | -|||||||
| Switzerland | -0 | -297,329 | -0 | -0 | -0 | -297,329 | -|||||||
| Tanzania U Rep | -0 | -75,000 | -0 | -0 | -0 | -75,000 | -|||||||
| Uganda | -0 | -98,034 | -0 | -0 | -0 | -98,034 | -|||||||
| United Kingdom | -3 | -1,666,276 | -0 | -0 | -3 | -1,666,276 | -|||||||
| Zambia | -0 | -80,028 | -0 | -0 | -0 | -80,028 | -|||||||
| Total | -32 | -$18,812,263 | -2 | -$989,701 | -34 | -$19,801,964 | +Australia | +4 | +$2,681,681 | +0 | +$0 | +4 | +$2,681,681 | +
| Belgium | +1 | +$131,854 | +0 | +$0 | +1 | +$131,854 | +|||||||
| Canada | +12 | +$6,604,118 | +0 | +$0 | +12 | +$6,604,118 | +|||||||
| Ethiopia | +0 | +$250,000 | +0 | +$0 | +0 | +$250,000 | +|||||||
| France | +7 | +$3,583,009 | +0 | +$0 | +7 | +$3,583,009 | +|||||||
| Germany | +5 | +$2,041,735 | +0 | +$0 | +5 | +$2,041,735 | +|||||||
| Ghana | +1 | +$234,901 | +0 | +$0 | +1 | +$234,901 | +|||||||
| Israel | +2 | +$317,969 | +0 | +$0 | +2 | +$317,969 | +|||||||
| Italy | +1 | +$134,258 | +0 | +$0 | +1 | +$134,258 | +|||||||
| Jamaica | +0 | +$50,000 | +0 | +$0 | +0 | +$50,000 | +|||||||
| Kenya | +1 | +$333,259 | +0 | +$0 | +1 | +$333,259 | +|||||||
| Netherlands | +2 | +$254,375 | +0 | +$0 | +2 | +$254,375 | +|||||||
| Nigeria | +0 | +$235,184 | +0 | +$0 | +0 | +$235,184 | +|||||||
| Norway | +1 | +$74,043 | +0 | +$0 | +1 | +$74,043 | +|||||||
| Rwanda | +1 | +$475,730 | +0 | +$0 | +1 | +$475,730 | +|||||||
| South Africa | +5 | +$753,703 | +0 | +$0 | +5 | +$753,703 | +|||||||
| Spain | +1 | +$102,979 | +0 | +$0 | +1 | +$102,979 | +|||||||
| Switzerland | +1 | +$865,228 | +0 | +$0 | +1 | +$865,228 | +|||||||
| Thailand | +0 | +$70,000 | +0 | +$0 | +0 | +$70,000 | +|||||||
| Uganda | +1 | +$305,169 | +0 | +$0 | +1 | +$305,169 | +|||||||
| United Kingdom | +22 | +$5,320,242 | +0 | +$0 | +22 | +$5,320,242 | +|||||||
| + Total + | ++ 68 + | ++ $24,819,437 + | ++ 0 + | ++ $0 + | ++ 68 + | ++ $24,819,437 + |
This page presents tables comparing of NCI's budget, full-time equivalent (FTE) positions, and occupied space from fiscal years 2011 through 2021.
-In this table, funds represent obligations against the annual appropriation in millions of dollars. Fiscal years 2017 through 2021 figures include the Cancer Moonshot℠ funding. FTEs are the number of work years for appointed employees of the NCI. A work year equals 2,080 hours. Space is in thousands of square feet, excluding NCI-Frederick.
-The increase in space (Sq Ft) during FY 2013 is due to NCI’s lease of its Shady Grove complex, a new consolidated facility in Rockville, MD. This facility has the advantage of providing additional space for NCI scientific programs, and includes conference and meeting rooms, a cafeteria, and a data center that serves multiple NCI facilities. During FY 2013, NCI was working to decommission their vacated leased facilities, and continued to lease a portion of them while completing the decommissioning process.
-The 2016 FTE count has been updated to include Commissioned Corp staff.
- - ++ This page presents tables comparing NCI's budget, full-time equivalent (FTE) + positions, and occupied space spanning fiscal years 2015 through 2024. +
++ NCI's budget is displayed in millions of dollars and includes the Cancer + Moonshot℠ funding in fiscal years 2017 through 2023. FTEs are the number of + work years for appointed employees of NCI. A work year equals 2,080 hours. + Space is in thousands of square feet, excluding NCI's Frederick National + Laboratory for Cancer Research. +
++ In fiscal year 2020, NCI acquired new laboratory space (called the + Consolidated Research Lab) in Shady Grove and new administrative space in + Bethesda. +
+ +- ## Research Career Awards “K” Program - -- entity: "block_content" - type: "raw_html_block" - info: "Factbook-html-bar" +- entity: 'block_content' + type: 'raw_html_block' + info: 'Factbook-html-bar' info__ES: value: langcode: en status: 1 field_raw_html: - - format: "raw_html" + - format: 'raw_html' value: | - + field_raw_html__ES: - - format: "raw_html" + - format: 'raw_html' value: -- entity: "block_content" - type: "raw_html_block" - info: "Factbook-kawards-pie" +- entity: 'block_content' + type: 'raw_html_block' + info: 'Factbook-kawards-pie' info__ES: value: langcode: en status: 1 field_raw_html: - - format: "raw_html" + - format: 'raw_html' value: | - + field_raw_html__ES: - - format: "raw_html" + - format: 'raw_html' value: -- entity: "node" - type: "cgov_article" +- entity: 'node' + type: 'cgov_article' langcode: en status: 1 moderation_state: @@ -1148,20 +2228,19 @@ computed_path: '/about-nci/budget/fact-book/extramural-programs/k-awards' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -
The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI’s training effort.
++ The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI’s training effort. +
- - -- +
- -
- ## Extramural Funding - -- entity: "block_content" - type: "raw_html_block" - info: "Factbook-html-extramural" +- entity: 'block_content' + type: 'raw_html_block' + info: 'Factbook-html-extramural' info__ES: value: langcode: en status: 1 field_raw_html: - - format: "raw_html" + - format: 'raw_html' value: | - + field_raw_html__ES: - - format: "raw_html" + - format: 'raw_html' value: -- entity: "node" - type: "cgov_article" +- entity: 'node' + type: 'cgov_article' langcode: en status: 1 moderation_state: value: 'published' - title: "Extramural Funding" - field_browser_title: "2021 NCI Budget Fact Book - Extramural Funding" - field_page_description: "Find details about obligations for the NCI extramural research program, including grants and contracts." - field_card_title: "Extramural Funding" + title: 'Extramural Funding' + field_browser_title: '2021 NCI Budget Fact Book - Extramural Funding' + field_page_description: 'Find details about obligations for the NCI extramural research program, including grants and contracts.' + field_card_title: 'Extramural Funding' field_card_description: value: | Find details about obligations for grants and contracts this fiscal year. @@ -1223,137 +2297,175 @@ computed_path: '/about-nci/budget/fact-book/data/extramural' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -
Overall, NCI obligations for its extramural program, which includes grants and contracts, totaled $4.88 billion in FY 2021.
- ++ Overall, NCI obligations for its extramural program, including grants and + contracts, totaled $5.35 billion in fiscal year 2024. +
Obligations on this page include FY 2021 Cancer Moonshot funding and excludes fiscal years 2017 through 2020 Cures Moonshot carryover obligations.
- - - +| Mechanism | -Amount | -Percent | +
|---|---|---|
| + Mechanism + | ++ Amount + | ++ Percent + |
| Research & Development (R&D) Contracts | -$812,246,516 | -16.7% | -
| Buildings and Facilities | -30,000,000 | -0.6% | -
| Construction Contracts | -0 | -0.0% | -
| Subtotal Contracts | -$842,246,516 | -17.3% | -
| Research Project Grants (RPGs) | -2,822,414,508 | -57.9% | -
| Cancer Centers/Specialized Centers/SPORES | -563,521,069 | -11.6% | -
| NRSA | -92,995,313 | -1.9% | -
| Other Research Grants | -556,149,380 | -11.4% | -
| Subtotal Grants | -$4,035,080,270 | -82.7% | -
| Total Extramural Funds | -$4,877,326,786 | -100.0% | -
| Intramural/RMS Funds | -1,565,408,450 | -- |
| Total NCI | -$6,442,735,236 | +|
| + Research & Development (R&D) Contracts + | +$888,211,673 | +16.6% | +
| Buildings and Facilities | +$30,000,000 | +0.6% | +
| Construction Contracts | +$0 | +0.0% | +
| + Subtotal Contracts + | ++ $918,211,673 + | ++ 17.2% + | +
| Research Project Grants (RPGs) | +$3,129,796,011 | +58.5% | +
| + Cancer Centers/Specialized Centers/SPORES + | +$606,359,172 | +11.3% | +
| NRSA | +$89,878,259 | +1.7% | +
| Other Research Grants | +$606,416,274 | +11.3% | +
| + Subtotal Grants + | ++ $4,432,449,716 + | ++ 82.8% + | +
| Total Extramural Funds | +$5,350,661,389 | +100.0% | +
| Intramural/RMS Funds | +$1,870,255,014 | ++ |
| + Total NCI + | ++ $7,220,916,403 + | |
This trainee award program is named after Dr. Ruth L. Kirschstein, a polio vaccine researcher and a champion of research training and inclusion of underrepresented individuals in the scientific workforce. Dr. Kirschstein was the first woman to become director of an NIH institute.
-The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to meet the Nation’s biomedical, behavioral, and clinical research needs.
-NRSA for Individual Predoctoral MD/PhD Degree Fellows (F30)
-NRSA for Individual Predoctoral Fellows (F31)
-NRSA for Individual Postdoctoral Fellows (F32)
- -NRSA Institutional Research Training Grant (T32)
- - ++ This trainee award program is named after Dr. Ruth L. Kirschstein, a polio + vaccine researcher and a champion of research training and inclusion of + underrepresented individuals in the scientific workforce. Dr. Kirschstein was + the first woman to become director of an NIH institute. +
++ The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program + helps ensure that a diverse pool of highly trained scientists is available in + appropriate scientific disciplines to meet the nation’s biomedical, + behavioral, and clinical research needs. +
++ NRSA for Individual Predoctoral MD/PhD Degree Fellows (F30) +
++ NRSA for Individual Predoctoral Fellows (F31) +
++ NRSA for Individual Postdoctoral Fellows (F32) +
++ NRSA Institutional Research Training Grant (T32) +
+- ## NIH Management Fund -- entity: "block_content" - type: "raw_html_block" - info: "Factbook-HTML-ManagementFund" +- entity: 'block_content' + type: 'raw_html_block' + info: 'Factbook-HTML-ManagementFund' info__ES: value: langcode: en status: 1 field_raw_html: - - format: "raw_html" + - format: 'raw_html' value: | - + field_raw_html__ES: - - format: "raw_html" + - format: 'raw_html' value: -- entity: "node" - type: "cgov_article" +- entity: 'node' + type: 'cgov_article' langcode: en status: 1 moderation_state: value: 'published' - title: "NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent" + title: 'NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent' field_browser_title: - value: "2021 NCI Budget Fact Book - NIH Management Fund" + value: '2021 NCI Budget Fact Book - NIH Management Fund' field_page_description: value: "See the distribution of NCI's payment for common research and support activities required by NIH, including GSA Rent and the Service and Supply Fund." field_card_title: - value: "NIH Management Fund" + value: 'NIH Management Fund' field_card_description: value: "See the distribution of NCI's payment for common research and support activities required by NIH." field_site_section: @@ -1430,141 +2582,212 @@ computed_path: '/about-nci/budget/fact-book/data/management-fund' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -
The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:
-Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, social work, drug costs, red team response, bench to bedside and the Children's Hospital.
-Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.
-Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.
-Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.
-Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, biomedical engineering, background investigations, IT cybersecurity and GSA rental payments for space (to include all building rental costs, including utilities and guard services).
- - - ++ The NIH Management Fund provides the financing for certain common research and + administrative support activities that are required in the operations of NIH: +
++ Clinical Center: Admissions and follow-up, + anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood + bank, rehabilitation medicine, pharmacy, medical records, nursing services, + patient nutrition services, housekeeping services, laundry, social work, drug + costs, red team response, bench to bedside, and the children's hospital. +
++ Center for Scientific Review: Initial scientific review + of applications and assignment of research grant applications to institutes. +
++ Center for Information Technology: Research and + development program that applies concepts and methods of computer science are + applied to biomedical problems. +
++ Other Research Services: Procurement, safety, + engineering, biomedical engineering, veterinary resources, and library + services have moved to Service and Supply fund. +
++ Service and Supply Fund: Mainframe computing, enterprise + IT software planning and development, engineering planning and design, + printing, telecommunications, procurement, shipping and receiving, motor pool, + research animals, fabrication and maintenance of scientific equipment, + utilities and plant maintenance, biomedical engineering, background + investigations, IT cybersecurity, and General Services Administration (GSA) + rental payments for space (including all building rental costs, utilities and + guard services) and Other Research Services (to include procurement, safety, + engineering and biomedical engineering). +
+- -
| Distribution of NCI Payment | -Amount | -Share of NCI | -||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Center | -$172,120,358 | -38.0% | -||||||||||
| Center for Scientific Review | -22,765,248 | -5.0% | -||||||||||
| Center for Information Technology | -40,262,648 | -8.9% | -||||||||||
| Service & Supply Fund Assessment | -205,569,289 | -45.3% | -||||||||||
| Other Research Services | -12,777,921 | -2.8% | -||||||||||
| Other OD | -0 | -0.0% | -||||||||||
| Total NCI Management Fund & SSF | -$453,495,464 | -100.0% | -||||||||||
| + Distribution of NCI Payment + | ++ Amount + | ++ Share of NCI + | +
|---|---|---|
| Clinical Center | +$200,170,867 | +39.0% | +
| Center for Scientific Review | +$22,983,336 | +4.5% | +
| Center for Information Technology | +$42,428,424 | +8.3% | +
| Service & Supply Fund Assessment | +$247,660,891 | +48.3% | +
| Other Research Services | +$0 | +0.0% | +
| Other OD | +$0 | +0.0% | +
| + Total NCI Management Fund & SSF + | ++ $513,243,518 + | ++ 100.0% + | +
| Type | -Amount | -Percent | -||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCI | -$453,495,464 | -19.9% | -||||||||||
| Other NIH Institutes | -$1,819,830,999 | -80.1% | -||||||||||
| Total NIH Management Fund & SSF | -$2,273,326,463 | -100% | -||||||||||
| + Type + | ++ Amount + | ++ Percent + | +
|---|---|---|
| NCI | +$513,243,518 | +20.2% | +
| All Other NIH Institutes | +$2,026,027,574 | +79.8% | +
| + Total NIH Management Fund & SSF + | ++ $2,539,271,091 + | ++ 100% + | +
With over $190 million appropriated for Cancer Moonshot activities in fiscal year (FY) 2021, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support, as shown in the chart below.
++ With over $117 million carryover funds for Cancer Moonshot activities in + fiscal year (FY) 2024, funding was allocated into four budget mechanisms: + research grants, R&D contracts, intramural research, and research + management and support, as shown in the chart below. +
- +Similar to the institute’s annual appropriation, NCI reports Cancer Moonshot obligations by funding mechanism.
- -| Type of Mechanism | -Mechanism | -Number | -Amount1 | +
|---|---|---|---|
| + Type of Mechanism + | ++ Mechanism + | ++ Number + | ++ Amount1 + |
| Research Project Grants (RPGs) | -Competing | -7 | -$1,818,651 | -
| Noncompeting | -58 | -$60,399,839 | -|
| Administrative Supplements | -20 | -$4,762,599 | -|
| Subtotal, without SBIR | -65 | -$66,981,088 | -|
| SBIR/STTR Grants | -2 | -$858,796 | -|
| Subtotal, RPGs | -67 | -$67,839,884 | -|
| Centers | -Cancer Centers Grants-P30s | -1 | -$4,747,685 | -
| P50s | -7 | -$8,382,195 | -|
| Cooperative Agreements-U54s/U41s | -15 | -$13,244,735 | -|
| Subtotal, Centers | -23 | -$26,374,615 | -|
| Other Research | -Resource Grants-U24s/U2Cs | -11 | -
- $28,722,409 - |
-
| Subtotal, Other Research | -11 | -
- $28,722,409 - |
- |
| Subtotal, Research Grants | -- | 103 | -
- $122,936,908 - |
-
| Intramural Research | -Program | -0 | -
- $49,648,875 - |
-
| Research Management & Support | -RMS | -0 | -
- $0 - |
-
| R&D Contracts | -R&D Contracts | -17 | -
- $27,393,003 - |
-
| SBIR/STTR Contracts | -7 | -
- $6,257,004 - |
- |
| Subtotal, R&D Contracts | -24 | -
- $33,650,007 - |
- |
| Total | -- | - |
- $206,235,789 + |
|
+ + Research Project Grants (RPGs) + ++ + |
+ Competing | +21 | +$16,985,816 | +
| Noncompeting | +32 | +$21,070,638 | +|
| Admin Supplements | +0 | +$2,653,674 | +|
| Subtotal, without SBIR | +0 | +$0 | +|
| SBIR/STTR Grants | +0 | +$0 | +|
| Subtotal, RPGs | +53 | +$40,710,128 | +|
|
+ + Centers + ++ |
+ Cancer Centers-P30s | +0 | +$721,495 | +
| P50s | +2 | +$862,041 | +|
| Cooperative Agreements-U54s/U41s | +1 | +$267,596 | +|
| Subtotal, Centers | +3 | +$1,851,132 | +|
|
+ + Other Research + ++ |
+ Resource Grants-U24s/U2Cs | ++ | $25,665,318 | +
| Subtotal, Other Research | ++ | $25,665,318 | +|
| + Subtotal, Research Grants + | ++ | + | + $68,226,578 + | +
| + Intramural Research + | +IR Program | +0 | ++ $4,960,447 + | +
| + Research Management & Support + | +RMS | +0 | +$141,095 | +
|
+ + R&D Contracts + ++ + |
+ R&D Contracts | ++ | $44,532,683 | +
| SBIR/STTR Contracts | ++ | $0 | +|
| Subtotal, R&D Contracts | ++ | $44,532,683 | +|
| + Total + | ++ | + | + $117,860,803 + | +
| + 1 Includes obligations and recoveries from fiscal + years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover + accounts. | |||
|
- 1 Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, and 2020 carryover accounts. - |
- |||
In fiscal year 2024, more than 72.5% of competing funds were used to support grants awarded either within the established payline or through Requests for Applications (RFAs). Of the total competing dollars, 12.4% specifically supported RFA-driven awards. The remaining funds were used to support grants made as exceptions to the standard funding range.
field_site_section: - '#process': callback: 'reference' @@ -1809,782 +3100,850 @@ computed_path: '/about-nci/budget/fact-book/extramural-programs/rpg' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' + field_body_section_heading: + value: 'Number of RPG Awards' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -During fiscal year 2021,
-The FY 2020 figures include FY 2020 Cancer Moonshot funds and the FY 2021 figures include FY 2021 Cancer Moonshot funds.
-The FY 2021 competing RPG average cost calculation includes multi-year funded grants with a 1 year average cost estimation.
-Includes Small Business Innovation Research and Small Business Technology Transfer Awards.
- Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.
| RPG Awards Funded | -2020 No. or % | -2020 Amount | -2021 No. or % | -2021 Amount | +RPG Awards Funded | +2023 No. or % | +2023 Amount | +2024 No. or % | +2024 Amount |
|---|---|---|---|---|---|---|---|---|---|
| Total Funding for RPGs | -5,070 | -2,771,666 | -5,210 | -2,822,415 | +5,736 | +$3,145,237 | +5,739 | +$3,129,796 | |
| SBIR/STTR | -217 | -151,141 | -238 | -158,269 | +228 | +$175,373 | +199 | +$158,454 | |
| Funding for RPGs without SBIR/STTR Program | -4,853 | -2,620,526 | -4,972 | -2,664,145 | +5,508 | +$2,969,864 | +5,540 | +$2,971,342 | |
| Continuation or Noncompeting Grants Funded | -3,636 | -1,814,161 | -3,641 | -1,886,072 | +4,139 | +$2,125,093 | +4,316 | +$2,174,188 | |
| Competing Grants Funded | -1,217 | -681,401 | -1,331 | -640,878 | +1,369 | +$697,786 | +1,224 | +$640,639 | |
| Administrative Supplements | -221 | -30,503 | -283 | -40,531 | +354 | +$39,659 | +436 | +$47,330 | |
| Partial Assessment for DHHS Program Evaluation | -- | 94,460 | -- | 96,664 | ++ | $107,326 | ++ | $109,184 |
| Grant Category | -R01 or Share | -2020 No. or % | -2020 Amount | -2021 No. or % | -2021 Amount | -
|---|---|---|---|---|---|
| Grants within Paylines | -- | 933 | -409,440 | -1,007 | -440,021 | -
| Traditional R01 | -714 | -352,832 | -733 | -376,081 | -|
| RFA Grants | -- | 93 | -143,328 | -151 | -83,636 | -
| Share of Competing Grant Funds | -21.0% | -- | 13.1% | -- | |
| Exception Grants | -- | 284 | -271,961 | -324 | -200,857 | -
| Share of Competing Grant Funds | -39.9% | -- | 31.3% | -- |
| Statistical Measure | -2020 | -2021 | -
|---|---|---|
| Total Competing Application Requests* | -9,538 | -9,601 | -
| Funding Success Rate | -13% | -14% | -
| Percentile Funding for R01 Grants | -10th & 15th | -11th & 16th | -
| Average Cost-Competing** | -$503 | -$486 | -
| Average Reduction from Recommended/Requested Levels | --14% | --14% | -
| *Excludes SBIR/STTR | -- | |
| **The FY 2021 competing RPG average cost calculation includes multi-year funded grants with a 1 year average cost estimation. | -- | |
| FY 2020 figures include FY 2020 Cancer Moonshot funds. | -- | |
| FY 2021 figures include FY 2021 Cancer Moonshot funds. | -- | |
The "Other" category includes DP1, DP2, DP5, R00, R37, U01, U19, UH2, UH3, UG3, UA5, R50, UM1, R15, R55 and R56 grant activities.
-Includes fiscal years 2020 and 2021 Cancer Moonshot funding and excludes all carryover obligations
- -| RPG Mechanism | -2020 | -2021 | -Description | -
|---|---|---|---|
| R01 Traditional Grants | -10th & 15th | -11th & 16th | -Percentile | -
| P01 Program Projects | -17% Reduction | -17% Reduction | -SPL Selected* | -
| R03 Small Grants | -25 | -25 | -Impact Score | -
| R15 Academic Research | -25 | -25 | -Impact Score | -
| R21 Exploratory Phase I | -9th | -9th | -Percentile | -
| R33 Exploratory Phase II | -N/A | -N/A | -SPL Selected* | -
| R41/R42 STTR | -26 | -28 | -Impact Score | -
| R43/R44 SBIR | -25 | -22 | -Impact Score | -
| *SPL = Scientific Program Leaders (NCI) | -|||
The following table displays requested and awarded RPGs and the success rate for fiscal years 2019 and 2020. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) awards. The Download the Data link contains data for the prior ten years.
- - - -| Fiscal Year | -Type | -Number Requested | -Amount Requested | -Number Awarded | -Amount Awarded | -Success Rate | -
|---|---|---|---|---|---|---|
| 2020 | -Competing New | -10,361 | -$4,866,693 | -1,210 | -$595,825 | -12.4% | -
| Competing Renewal | -463 | -385,101 | -136 | -161,312 | -||
| Competing Supplement | -28 | -7,485 | -4 | -885 | -||
| Competing Subtotal | -10,852 | -5,259,279 | -1,350 | -758,022 | -||
| Non-Competing | -- | - | 3,720 | -2,013,645 | -||
| FY 2020 RPG Total | -- | - | 5,070 | -$2,771,666 | -||
| 2021 - |
- Competing New | -10,080 | -$4,935,665 | -1,336 | -$630,816 | -14.1% - |
-
| Competing Renewal | -409 | -289,208 | -141 | -93,308 | -||
| Competing Supplement | -39 | -16,065 | -9 | -2,875 | -||
| Competing Subtotal | -10,528 | -5,240,938 | -1,486 | -726,998 | -||
| Non- Competing | -- | - | 3,724 | -2,095,416 | -||
| FY 2021 RPG Total | -- | - | 5,210 | -$2,822,415 | -||
| Includes Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Awards. | -||||||
| Success rate is the number of awarded grants divided by the number of awards requested. | -||||||
| Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021. | -||||||
This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit NIH Activity Codes for more information on the descriptions.
- - -| Year | -Total No. Awarded | -Total Amount | -Average Cost | -||||||
|---|---|---|---|---|---|---|---|---|---|
| 2011 | -5,019 | -$2, 088,352 | -$416 | -||||||
| 2012 | -5,021 | -$2,075,295 | -$413 | -||||||
| 2013 | -4,816 | -$1,924,803 | -$400 | -||||||
| 2014 | -4,814 | -$1,939,623 | -$403 | -||||||
| 2015 | -4,767 | -$2,019,308 | -$424 | -||||||
| 2016 | -4,666 | -$2,068,869 | -$443 | -||||||
| *2017 | -4,663 | -$2,195,184 | -$471 | -||||||
| *2018 | -4,780 | -$2,366,530 | -$495 | -||||||
| *2019 | -4,984 | -$2,456,156 | -$493 | +Grant Category | +R01 or Share | +2023 No. or % | +2023 Amount | +2024 No. or % | +2024 Amount |
| *2020 | -5,070 | -$2,677,206 | -$514 | +Grants within Paylines | ++ | 1018 | +$481,920 | +888 | +$420,190 |
| **2021 | -5,210 | -$2,725,751 | -$523 | +Traditional R01 | ++ 776 + | +$428,468 | ++ 616 + | ++ $347,693 + | |
| RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award. | +RFA Grants | ++ | 115 | +$71,919 | +108 | +$79,166 | |||
| From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall. | +Share of Competing Grant Funds | +10.3% | ++ | 12.4% | +|||||
| *Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021. | +Exception Grants | ++ | 351 | +$215,866 | +336 | +$220,450 | |||
| **Fiscal year 2021 includes multi-year funded grants with a 1 year average cost estimation. | +Share of Competing Grant Funds | +30.9% | ++ | 34.4% | +|||||
| Grant Code | -2020 - Number |
- 2020 - Amount |
- 2021 Number | -2021 Amount | +Statistical Measure | +2023 | +2024 |
|---|---|---|---|---|---|---|---|
| R01 | -3,316 | -$1,555,105 | -3,448 | -$1,622,714 | +*Excludes SBIR/STTR | ||
| DP1 | -1 | -1,197 | -0 | -0 | +Total Competing Application Requests* | +8,618 | +8,990 |
| DP2 | -0 | -0 | -0 | -0 | +Funding Success Rate | +16% | +14% |
| DP5 | -0 | -0 | -0 | -0 | +Percentile Funding for R01 Grants | +12th & 17th | +10th & 17th |
| P01 | -93 | -187,766 | -96 | -196,613 | +Average Cost-Competing | +$510 | +$523 |
| R00 | -95 | -23,566 | -78 | -18,841 | ++ Average Reduction from Recommended/Requested Levels + | +-14% | +-14% |
+ The "Other" category includes DP1, DP2, DP5, R00, R37, U01, U19,UH2, UH3, UG3, + UA5, R50, UM1, R15, R55 and R56 activities. +
+| R37 | -156 | -71,569 | -220 | -100,632 | +RPG Mechanism | +2023 | +2024 | +Description |
|---|---|---|---|---|---|---|---|---|
| *RFA | -0 | -0 | -0 | -0 | +*SPL = Scientific Program Leaders (NCI) | |||
| U01 | -300 | -257,018 | -304 | -238,270 | +R01 Traditional Grants | +12th & 17th | +10th & 17th | +Percentile |
| U19 | -2 | -6,335 | -6 | -10,052 | +P01 Program Projects | +17% Reduction | +17% Reduction | +SPL Selected* |
| UH2 | -7 | -1,573 | -7 | -1,603 | +R03 Small Grants | +25 | +25 | +Impact Score |
| R35 | -154 | -145,771 | -166 | -158,472 | +R15 Academic Research | +25 | +25 | +Impact Score |
| R50 | -96 | -15,799 | -77 | -12,889 | +R21 Exploratory Phase I | +9th | +10th | +Percentile |
| UH3 | -36 | -20,106 | -29 | -19,204 | +R33 Exploratory Phase II | +N/A | +N/A | +SPL Selected* |
| UA5 | -0 | -0 | -0 | -0 | +R41/R42 STTR | +26 | +25 | +Impact Score |
| UM1 | -23 | -102,669 | -15 | -55,880 | +R43/R44 SBIR | +27 | +25 | +Impact Score |
+ The following table displays requested and awarded RPGs and the success rate for fiscal years 2023 and 2024. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) awards. The Download the Data link contains data for the prior ten years. +
+ +| UG3 | -8 | -4,387 | -13 | -10,917 | +Fiscal Year | +Type | +Number Requested | +Amount Requested | +Number Awarded | +Amount Awarded | +Success Rate | +|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R03 | -119 | -11,689 | -93 | -8,383 | ++ 2023 + | +Competing New | +9,302 | +$4,888,297,784 | +1,319 | +$653,918 | ++ 15.4% + | +|
| R21 | -387 | -92,517 | -367 | -89,334 | +Competing Renewal | +427 | +$341,237,643 | +179 | +$130,281 | +|||
| R33 | -37 | -19,351 | -34 | -16,535 | +Competing Supplement | ++ | + | 0 | +$0 | +|||
| R15 | -22 | -9,299 | -18 | -7,018 | ++ Competing Subtotal + | ++ 9,729 + | ++ $5,229,535,427 + | ++ 1,498 + | ++ $784,199 + | +|||
| R55 | -0 | -0 | -0 | -0 | +Non-Competing | ++ | + | 4,238 | +$2,253,712 | +|||
| R56 | -1 | -345 | -1 | -122 | ++ FY 2023 RPG Total + | ++ | + | + 5,736 + | ++ $3,037,911 + | +|||
| RC2 | -0 | -0 | -0 | -0 | +
+ 2024 + + |
+ Competing New | +9,932 | +$5,470,395 | +1,177 | +$608,278 | +
+ 12.8% + + |
+ |
| SBIR/STTR | -217 | -151,141 | -238 | -158,269 | +Competing Renewal | +413 | +$347,341 | +145 | +$100,450 | +|||
| Total | -5,070 | -$2,677,206 | -5,210 | -$2,725,751 | +Competing Supplement | +8 | +$2,005 | +3 | +$515 | +|||
| RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award. | -+ | + Competing Subtotal + | ++ 10,353 + | ++ $5,819,741 + | ++ 1,325 + | ++ $709,243 + | ||||||
| From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall. | -+ | Non- Competing | ++ | + | 4,414 | +$2,311,369 | ||||||
| Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020. | -+ | + FY 2024 RPG Total + | ++ | + | + 5,739 + | ++ $3,020,612 + | ||||||
| Fiscal year 2021 includes multi-year funded grants with a 1 year average cost estimation. | -- | + | + Includes Small Business Innovation Research and Small Business + Technology Transfer (SBIR/STTR) Awards. + | +|||||||||
| + FY 2020-2023 figures include Cancer MoonshotSM + funding data. + | +||||||||||||
| + Success rate is the number of awarded grants divided by the number of + awards requested. + | +||||||||||||
| + Includes FY 2023 Cancer Moonshot funding. Excludes FY 2017 through + FY2022 Moonshot carryover obligations. + | ||||||||||||
+ This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit NIH Activity Codes for more information on the descriptions. +
+ +| Year | +Total No. Awarded | +Total Amount | +Average Cost | +
|---|---|---|---|
| 2014 | +4,814 | +$1,939,623 | +$403 | +
| 2015 | +4,767 | +$2,019,308 | +$424 | +
| 2016 | +4,666 | +$2,068,869 | +$443 | +
| 2017 | +4,663 | +$2,195,184 | +$471 | +
| 2018 | +4,780 | +$2,366,530 | +$495 | +
| 2019 | +4,984 | +$2,456,156 | +$493 | +
| 2020 | +5,070 | +$2,677,206 | +$514 | +
| 2021 | +5,221 | +$2,739,345 | +$525 | +
| 2022 | +5,505 | +$2,871,997 | +$522 | +
| 2023 | +5,736 | +$3,037,911 | +$530 | +
| 2024 | +5,739 | +$3,020,612 | +$526 | +
| Grant Code | +
+ 2023 + Number + |
+
+ 2023 + Amount + |
+ 2024 Number | +2024 Amount | +
|---|---|---|---|---|
| R01 | +3,725 | +$1,864,401 | +3,698 | +$1,842,927 | +
| DP1 | +0 | +$0 | +2 | +$1,090 | +
| DP2 | +0 | +$356 | +0 | +$20 | +
| DP5 | +0 | +$0 | +0 | +$0 | +
| P01 | +96 | +$197,631 | +90 | +$187,561 | +
| R00 | +104 | +$25,555 | +115 | +$28,296 | +
| R37 | +343 | +$164,733 | +381 | +$180,953 | +
| U01 | +321 | +$236,674 | +333 | +$234,896 | +
| U19 | +7 | +$12,552 | +10 | +$15,494 | +
| U34 | +1 | +$284 | +2 | +$564 | +
| UH2 | +5 | +$1,057 | +4 | +$937 | +
| R34 | +3 | +$881 | +15 | +$4,384 | +
| R35 | +133 | +$127,082 | +120 | +$112,120 | +
| R50 | +94 | +$16,474 | +111 | +$19,286 | +
| UH3 | +30 | +$24,463 | +29 | +$22,827 | +
| UA5 | +0 | +$0 | +0 | +$0 | +
| UM1 | +21 | +$53,731 | +19 | +$55,120 | +
| UG3 | +3 | +$4,126 | +18 | +$16,176 | +
| R03 | +108 | +$9,508 | +102 | +$10,375 | +
| R21 | +433 | +$93,605 | +395 | +$96,400 | +
| R33 | +43 | +$16,046 | +47 | +$16,996 | +
| R15 | +20 | +$9,050 | +20 | +$9,213 | +
| R55 | +0 | +$0 | +0 | +$0 | +
| R56 | +5 | +$1,220 | +4 | +$1,006 | +
| R61 | +13 | +$3,108 | +25 | +$5,515 | +
| RC2 | +0 | +$0 | +0 | +$0 | +
| SBIR/STTR | +228 | +$175,373 | +199 | +$158,454 | +
| + Total + | ++ 5,736 + | +$3,037,911 | ++ 5,739 + | +$3,020,612 | +
All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below organize NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.
field_site_section: - '#process': callback: 'reference' @@ -2622,1264 +3985,2032 @@ computed_path: '/about-nci/budget/fact-book/data/obligations' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' + field_body_section_heading: + value: 'NCI Obligations by Mechanism' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below display NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.
-- -
Other Research mechanisms includes the following grants: Career Programs (K Awards), Cancer Education, Clinical Cooperative Groups, Pre-Doc Post-Doc Transition Awards, Education Projects - Cooperative Agreements, Minority Biomedical Research Support, Research Pathway in Residency, Pilot Research Project, Resource Grants, International Research Training grants, Cooperative Conference Agreements, Conference grants, and Other Transaction Authority (OTA).
- -| Type of Mechanism | -Mechanism | -Number | -Amount | -% of Total Amount | +||||
|---|---|---|---|---|---|---|---|---|
| + Type of Mechanism + | ++ Mechanism + | ++ Number + | ++ Amount + | ++ % of Total Amount + | ||||
| Research Project Grants (RPGs) | -Non-Competing | -
- 3,641 - |
- $1,982,735,492 | -30.8% | -||||
| Administrative Supplements | -283 | -40,531,153 | -0.6% | -|||||
| Competing | -1,331 | -640,878,364 | -9.9% | -|||||
| Subtotal, without SBIR/STTR Grants | -4,972 | -$2,664,145,009 | -41.4% | -|||||
| SBIR/STTR Grants | -238 | -158,269,499 | -2.5% | -|||||
| Subtotal, RPGs | -5,210 | -2,822,414,508 | -43.8% | -|||||
| Centers & SPOREs | -Cancer Centers Grants-P20/P30 | -32 | -344,697,904 | -5.4% | -||||
| SPOREs | -64 | -119,570,354 | -1.9% | -|||||
| Other P50s/P20s | -57 | -3,306,038 | -0.1% | -|||||
| Other Specialized Centers | -79 | -95,946,773 | -1.5% | -|||||
| Subtotal, Centers | -232 | -$563,521,069 | -8.7% | -|||||
| Other Research | -Career Program | -- | - | - | ||||
| Post-Doc-Fellow Awards-K00 | -78 | -7,211,442 | -0.1% | -|||||
| Temin & Minority Mentored Awards-K01/K43 | -35 | -5,573,009 | -0.1% | -|||||
| Estab. Inv. Award-K-05 | -0 | -0 | -0.0% | -|||||
| Preventive Oncology-K07 | -30 | -4,964,775 | -0.1% | -|||||
| Clinical Investigator-K08 | -219 | -48,478,974 | -0.8% | -|||||
| Clinical Oncology-K12 | -20 | -14,506,693 | -0.2% | -|||||
| Transitional Career Development-K22 | -52 | -9,722,676 | -0.2% | -|||||
| Mentored Patient Oriented RCDA-K23 | -3 | -534,675 | -0.0% | -|||||
| Mid-Career Invest. & Patient Orient. Res-K24 | -2 | -354,197 | -0.0% | -|||||
| Mentored Quant. Res Career-K25 | -1 | -157,167 | -0.0% | -|||||
| Mentored Career Devel/Tem Intl Career-K43 | -1 | -551,375 | -0.0% | -|||||
| Pathway to Independence Awards K99 | -83 | -10,600,361 | -0.2% | -|||||
| Subtotal, Career Program | -524 | -$102,655,344 | -1.6% | -|||||
| Cancer Education Program-R25(including BD2K) | -68 | -17,632,838 | -0.3% | -|||||
| Clinical Cooperative Groups-U10/UG1 | -106 | -299,980,858 | -4.7% | -|||||
| PreDoc PostDoc Transition Awards-F99 | -44 | -1,770,090 | -0.0% | -|||||
| UE5 Education Projects | -5 | -2,045,516 | -0.0% | -|||||
| Minority Biomedical Support-S06 | -0 | -1,497,039 | -0.0% | -|||||
| Research Pathway in Residency (R38) | -3 | -608,718 | -0.0% | -|||||
| Pilot Research Project-OT2 | -1 | -3,308,166 | -0.1% | -|||||
| Resource Grants-R24/U24/U2C | -81 | -124,345,645 | -1.9% | -|||||
| Cooperative Conference Agreements-U13/R13 | -25 | -434,014 | -0.0% | -|||||
| Int'l Research Training Grants Conference- D43/U2R | -4 | -1,871,152 | -0.0% | -|||||
| Subtotal, Career and Other Research Grants | -861 | -$556,149,380 | -8.6% | -|||||
| Subtotal, Research Grants | -- | 6,303 | -$3,942,084,957 | -61.2% | -||||
| National Research Service Award (NRSA) Fellowships | -Trainees | -1,628 | -92,995,313 | -1.4% | -||||
| R&D Contracts | -R&D Contracts | -403 | -668,612,032 | -10.4% | -||||
| SBIR Contracts | -44 | -20,916,852 | -0.3% | -|||||
| NIH Management Fund/SSF Assessment | -0 | -122,717,632 | -1.9% | -|||||
| Subtotal, Contracts | -403 | -$812,246,516 | -12.6% | -|||||
| Intramural Research | -Program | -- | 830,641,566 | -12.9% | -||||
| NIH Management Fund/SSF Assessment | -- | 271,890,333 | -4.2% | -|||||
| Subtotal, Intramural Research (FTEs) | -1,766 | -$1,102,531,899 | -17.1% | -|||||
| Research Management & Support (RMS) | -Research Management and Support (RMS) | -- | 350,205,851 | -5.4% | -||||
| SBIR RMS | -- | 3,056,688 | -0.0% | -|||||
| NIH Management Fund/SSF Assessment | -- | 109,614,012 | -1.7% | -|||||
| Subtotal, RMS (FTEs) | -1,331 | -$462,876,551 | -7.2% | -|||||
| Buildings & Facilities | -- | - | 30,000,000 | -0.5% | -||||
| *Total NCI | -(FTEs) | -3,097 | -$6,442,735,236 | -100.0% | -||||
| All items in italics are non add entries. | -+ | |||||||
| + Research Project Grants (RPGs) + | +Non-Competing | +4,316 | +$2,286,467,147 | +31.7% | +||||
| Administrative Supplements | ++ 438 + | +$47,845,108 | +0.7% | +|||||
| Competing | +1,224 | +$637,029,310 | +8.8% | +|||||
| + Subtotal, without SBIR/STTR Grants + | ++ 5,978 + | ++ $2,971,341,565 + | ++ 41.1% + | +|||||
| SBIR/STTR Grants | +199 | +$158,454,446 | +2.2% | +|||||
| + Subtotal, RPGs + | ++ 6,177 + | ++ $3,129,796,011 + | ++ 43.3% + | +|||||
| + Centers & SPOREs + | +Cancer Centers Grants-P20/P30 | +83 | +$352,357,375 | +4.9% | +||||
| SPOREs | +68 | +$111,275,432 | +1.5% | +|||||
| Other P50s/P20s | +0 | +$5,105,142 | +0.1% | +|||||
| Other Specialized Centers | +97 | +$137,621,223 | +1.9% | +|||||
| + Subtotal, Centers + | ++ 248 + | ++ $606,359,172 + | ++ 8.4% + | +|||||
| + Other Research + | +Career Program | +0 | +$0 | +0.0% | ||||
| *Includes FY 2021 Cures-Moonshot funding. | -+ | Post-Doc-Fellow Awards-K00 | +87 | +$8,594,008 | +0.1% | +|||
| + Research Scientist Development Award-K01 + | +31 | +$4,894,207 | +0.1% | +|||||
| Academic/Teacher Award-K07 | +0 | +$0 | +0.0% | +|||||
| Clinical Investigator-K08 | +270 | +$62,528,453 | +0.9% | +|||||
| + Physician Scientist Award (Program)-K12 + | +28 | +$16,772,145 | +0.2% | +|||||
| + Transitional Career Development-K22 + | +57 | +$10,175,821 | +0.1% | +|||||
| Mentored Quant. Res Career-K25 | +3 | +$532,509 | +0.0% | |||||
| *Excludes FY 2020 through FY 2017 Cures-Moonshot carryover obligations. | -+ | + Early Stage Mentored Research and Career Development-K38 + | +2 | +$204,439 | +0.0% | +|||
| + International Research Career Development Award-K43 + | +6 | +$402,742 | +0.0% | +|||||
| Career Transition Award-K99 | +75 | +$10,590,692 | +0.1% | +|||||
| + Subtotal, Career Program + | ++ 559 + | ++ $114,695,016 + | ++ 1.6% + | +|||||
| + Cancer Education Program-R25 (including BD2K) + | +83 | +$23,600,697 | +0.3% | +|||||
| + Clinical Cooperative Groups-U10/UG1 + | +125 | +$302,941,755 | +4.2% | +|||||
| + PreDoc PostDoc Transition Awards-F99 + | +0 | +$1,865,834 | +0.0% | +|||||
| UE5 Education Projects | +0 | +$696,473 | +0.0% | +|||||
| + Minority Biomedical Support-S06 + | +0 | +$2,637,067 | +0.0% | +|||||
| + Research Pathway in Residency (R38) + | +0 | +$1,209,461 | +0.0% | +|||||
| + Other Transaction Authority-OT2 + | +0 | +$33,182,197 | +0.5% | +|||||
| Resource Grants-R24/U24/U2C | +0 | +$121,424,554 | +1.7% | +|||||
| + Cooperative Conference Agreements-U13/R13 + | +0 | +$993,994 | +0.0% | +|||||
| + International Research Training Grants- D43 + | +0 | +$2,469,226 | +0.0% | +|||||
| + International Training Cooperative Agreement (U2R) + | +0 | +$700,000 | +0.0% | +|||||
| + Subtotal, Career and Other Research Grants + | +767 | +$606,416,274 | +8.4% | +|||||
| + + | ++ Subtotal, Research Grants + | ++ 7,192 + | ++ $4,342,571,457 + | ++ 60.1% + | +||||
| + National Research Service Award (NRSA) Fellowships + | ++ Trainees + | ++ 1,416 + | ++ $89,878,259 + | ++ 1.2% + | +||||
| + R&D Contracts + | +R&D Contracts | +404 | +$785,908,607 | +10.9% | +||||
| SBIR Contracts | +40 | +$33,124,877 | +0.5% | +|||||
| + NIH Management Fund/SSF Assessment + | +0 | +$69,178,189 | +1.0% | +|||||
| + Subtotal, Contracts + | ++ 444 + | ++ $888,211,673 + | ++ 12.3% + | +|||||
| + Intramural Research + | +Program | +1,873 | +$1,036,573,544 | +14.4% | +||||
| + NIH Management Fund/SSF Assessment + | +0 | +$308,819,457 | +4.3% | +|||||
| + Subtotal, Intramural Research (FTEs) + | ++ 1,873 + | ++ $1,345,393,001 + | ++ 18.6% + | +|||||
| + Research Management & Support (RMS) + | ++ Research Management and Support (RMS) + | +1,425 | +$399,339,819 | +5.5% | +||||
| SBIR RMS | +0 | +$4,487,150 | +0.1% | +|||||
| + NIH Management Fund/SSF Assessment + | +0 | +$121,035,044 | +1.7% | +|||||
| + Subtotal, RMS (FTEs) + | ++ 1,425 + | ++ $524,862,013 + | ++ 7.3% + | +|||||
| + Buildings & Facilities + | ++ | + 0 + | +$30,000,000 | ++ 0.4% + | +||||
| + *Total NCI + | ++ (FTEs) + | ++ 3,298 + | ++ $7,220,916,403 + | ++ 100.0% + | +||||
| + All items in italics are non-add entries. + | ||||||||
| Division | -Total | +
|---|---|
| + Division + | ++ Total + |
| Center for Cancer Research (CCR) | -$500,787,790 | +
| Center for Cancer Research (CCR) | +$641,825,063 |
| Division of Cancer Epidemiology and Genetics (DCEG) | -107,110,008 | +
| + Division of Cancer Epidemiology and Genetics (DCEG) + | +$139,536,294 |
| Division of Cancer Treatment and Diagnosis (DCTD) | -544,353,247 | +
| + Division of Cancer Treatment and Diagnosis (DCTD) + | +$552,026,623 |
| Division of Cancer Biology (DCB) | -41,428,916 | +
| Division of Cancer Biology (DCB) | +$59,593,673 |
| Division of Cancer Control and Population Sciences (DCCPS) | -131,165,654 | +
| + Division of Cancer Control and Population Sciences (DCCPS) + | +$157,821,619 |
| Division of Cancer Prevention (DCP) | -223,216,237 | +
| Division of Cancer Prevention (DCP) | +$237,232,654 |
| Division of Extramural Activities (DEA) | -19,737,071 | +
| Division of Extramural Activities (DEA) | +$23,102,950 |
| Office of the Director (OD) | -1,706,118,998 | +
| Office of the Director (OD) | +$1,700,717,388 |
| Total Division | -$5,841,398,976 | +
| + Total Division + | ++ $6,539,192,620 + |
| Type of Mechanism | -Mechanism | -Amount | ++ Type of Mechanism + | ++ Mechanism + | ++ Amount + |
|---|---|---|---|---|---|
| Intramural Research | -Program | -$500,787,790 | ++ Intramural Research + | +Program | +$641,825,063 |
| NIH Management Fund | -0 | +NIH Management Fund/SSF Assessment | +$0 | ||
| Total CCR | -- | $500,787,790 | ++ Total CCR + | ++ | + $641,825,063 + |
| Type of Mechanism | -Mechanism | -Amount | ++ Type of Mechanism + | ++ Mechanism + | ++ Amount + |
|---|---|---|---|---|---|
| R&D Contracts | -R&D Contracts | -$19,491,642 | ++ R&D Contracts + | +R&D Contracts | +$44,087,333 |
| SBIR Contracts | -0 | +SBIR Contracts | +$0 | ||
| Intramural Research | -Program | -87,618,367 | ++ Intramural Research + | +Program | +$95,448,961 |
| NIH Management Fund | -0 | +NIH Management Fund/SSF Assessment | +$0 | ||
| Total DCEG | -- | $107,110,008 | ++ Total DCEG + | ++ | + $139,536,294 + |
| Type of Mechanism | -Mechanism | -Amount | +|
|---|---|---|---|
| + Type of Mechanism + | ++ Mechanism + | ++ Amount + | |
| Centers & SPOREs | -Cancer Centers Grants-P20/P30 | -$0 | +|
| + Centers & SPOREs + | ++ Cancer Centers Grants-P20/P30 + | +$0 | |
| SPOREs-P50 | -110,212,968 | +||
| SPOREs-P50 | +$110,789,224 | ||
| Other P50s/P20s | -351,000 | +||
| Other P50s/P20s | +$0 | ||
| Other Specialized Centers | -8,513,327 | +||
| + Other Specialized Centers + | +$16,072,162 | ||
| Subtotal, Centers | -$119,077,295 | +||
| + Subtotal, Centers + | ++ $126,861,386 + | ||
| Other Research–Grants | -Cancer Education Program-R25 (including BD2K) | -0 | +|
| + Other Research–Grants + | ++ Cancer Education Program-R25 (including BD2K) + | +$0 | |
| Clinical Cooperative Groups-U10/UG1 | -161,679,221 | +||
| Education Projects-UE5 | +$0 | ||
| PreDoc PostDoc Transition Awards-F99 | -0 | +||
| + Clinical Cooperative Groups-U10/UG1 + | +$142,141,328 | ||
| Education Projects-UE5 | -0 | +||
| + PreDoc PostDoc Transition Awards-F99 + | +$0 | ||
| Minority Biomedical Support-S06 | -0 | +||
| + Minority Biomedical Support-S06 + | +$0 | ||
| Rsrch Pathway in Residency-R38 | -0 | ++ Rsrch Pathway in Residency-R38 + | +$0 |
| Pilot Research Project-OT2 | -0 | +Pilot Research Project-OT2 | +$0 |
| Resource Grants-R24/U24/U2C | -0 | +||
| Resource Grants-R24/U24/U2C | +$0 | ||
| Cooperative Conference Agreements-U13/R13 | -0 | +||
| + Cooperative Conference Agreements-U13/R13 + | +$0 | ||
| Int'l Research Training Grants-D43/U2R | -0 | +||
| + International Research Training Grants-D43/U2R + | +$0 | ||
| Subtotal, Other Research-Grants | -$161,679,221 | +||
| + Subtotal, Other Research-Grants + | ++ $142,141,328 + | ||
| Subtotal, Research Grants | -- | $280,756,516 | +|
| + Subtotal, Research Grants + | ++ | + $269,002,714 + | |
| R&D Contracts | -R&D Contracts | -201,622,622 | +|
| + R&D Contracts + | +R&D Contracts | +$215,884,882 | |
| SBIR Contracts | -0 | +||
| SBIR Contracts | +$0 | ||
| NIH Management Fund/SSF Assessment | -0 | ++ NIH Management Fund/SSF Assessment + | +$0 |
| Subtotal, Contracts | -$201,622,622 | +||
| + Subtotal, Contracts + | ++ $215,884,882 + | ||
| Research Management & Support (RMS) | -RMS | -61,974,109 | +|
| + Research Management & Support (RMS) + | +RMS | +$67,139,027 | |
| SBIR RMS | -0 | +||
| SBIR RMS | +$0 | ||
| NIH Management Fund/SSF Assessment | -0 | +||
| + NIH Management Fund/SSF Assessment + | +$0 | ||
| Subtotal, RMS | -$61,974,109 | +||
| + Subtotal, RMS + | ++ $67,139,027 + | ||
| Total DCTD | -- | $544,353,247 | +|
| + Total DCTD + | ++ | + $552,026,623 + |
| Type of Mechanism | -Mechanism | -Amount | +||
|---|---|---|---|---|
| + Type of Mechanism + | ++ Mechanism + | ++ Amount + | ||
| Centers & SPOREs | -Cancer Centers Grants-P20/P30 | -$0 | +||
| + Centers & SPOREs + | +Cancer Centers Grants-P20/P30 | +$0 | ||
| SPOREs-P50 | -0 | +|||
| SPOREs-P50 | +$0 | |||
| Other P50s/P20s | -300,688 | +|||
| Other P50s/P20s | +$375,635 | |||
| Other Specialized Centers | -29,264,757 | +|||
| Other Specialized Centers | +$43,852,991 | |||
| Subtotal, Centers | -$29,565,445 | +|||
| + Subtotal, Centers + | ++ $44,228,626 + | |||
|
- - - - -
| + Other Research-Grants + | ++ Subtotal, Other Research–Grants + | ++ $0 + | +|
| + Subtotal, Research Grants + | ++ | + $44,228,626 | -R&D Contracts | -0 |
| SBIR Contracts | -0 | +
+ + +
+ |
+ R&D Contracts | +$0 |
| NIH Management Fund/SSF Assessment | -0 | +SBIR Contracts | +$0 | |
| Subtotal, Contracts | -$0 | ++ NIH Management Fund/SSF Assessment + | +$0 | |
| Other Research-Grants | -Subtotal, Other Research–Grants | -$0 | +||
| + Subtotal, Contracts + | ++ $0 + | |||
| Research Management & Support (RMS) | -RMS | -11,863,471 | +||
| + Research Management & Support (RMS) + | +RMS | +$15,365,047 | ||
| SBIR RMS | -0 | +|||
| SBIR RMS | +$0 | |||
| NIH Management Fund | -0 | +|||
| + NIH Management Fund/SSF Assessment + | +$0 | |||
| Subtotal, RMS | -$11,863,471 | +|||
| + Subtotal, RMS + | ++ $15,365,047 + | |||
| Total DCB | -- | $41,428,916 | +||
| + Total DCB + | ++ | + $59,593,673 + |
| Type of Mechanism | -Mechanism | -Amount | +|||
|---|---|---|---|---|---|
| Type of Mechanism | +Mechanism | +Amount | |||
| Centers & SPOREs | -Cancer Centers Grants-P20/P30 | -$0 | +|||
| + Centers & SPOREs + | +Cancer Centers Grants-P20/P30 | +$0 | |||
| SPOREs-P50 | -0 | +||||
| SPOREs-P50 | +$0 | ||||
| Other P50s/P20s | -2,449,195 | +||||
| Other P50s/P20s | +$4,346,416 | ||||
| Other Specialized Centers | -0 | +||||
| Other Specialized Centers | +$9,243,218 | ||||
| Subtotal, Centers | -$2,449,195 | ++ Subtotal, Centers + | ++ $13,589,634 + | ||
| Other Research | -Cancer Education Program-R25 (including BD2K) | -0 | +|||
| + Other Research + | ++ Cancer Education Program-R25 (including BD2K) + | +$0 | |||
| Clinical Cooperative Groups-U10/UG1 | -0 | +||||
| Education Projects-UE5 | +$0 | ||||
| PreDoc PostDoc Transition Awards-F99 | -0 | +||||
| + Clinical Cooperative Groups-U10/UG1 + | +$0 | ||||
| Education Projects-UE5 | -0 | +||||
| + PreDoc PostDoc Transition Awards-F99 + | +$0 | ||||
| Minority Biomedical Support-S06 | -0 | +||||
| + Minority Biomedical Support-S06 + | +$0 | ||||
| Research Pathway in Residency-R38 | -0 | +||||
| + Research Pathway in Residency-R38 + | +$0 | ||||
| Pilot Research Project-OT2 | -0 | +Pilot Research Project-OT2 | +$0 | ||
| Resource Grants-R24/U24/U2C | -184,250 | +||||
| Resource Grants-R24/U24/U2C | +$0 | ||||
| Cooperative Conference Agreements-U13/R13 | -0 | +||||
| + Cooperative Conference Agreements-U13/R13 + | +$0 | ||||
| Int'l Research Training Grants-D43/U2R | -0 | +||||
| + International Research Training Grants-D43/U2R + | +$0 | ||||
| Subtotal, Other Research Grants | -$184,250 | +||||
| + Subtotal, Other Research Grants + | ++ $0 + | ||||
| Subtotal, Research Grants | -- | $2,633,445 | ++ Subtotal, Research Grants + | ++ | + $13,589,634 + | +
| + R&D Contracts + | +R&D Contracts | +$100,630,059 | |||
| R&D Contracts | -R&D Contracts | -90,093,987 | +|||
| SBIR Contracts | +$0 | ||||
| SBIR Contracts | -0 | +||||
| + NIH Management Fund/SSF Assessment + | +$0 | ||||
| Subtotal, Contracts | -$90,093,987 | +||||
| + Subtotal, Contracts + | ++ $100,630,059 + | ||||
| Research Management & Support (RMS) | -RMS | -38,438,222 | +|||
| + Research Management & Support (RMS) + | +RMS | +$43,601,926 | |||
| SBIR RMS | -0 | +||||
| SBIR RMS | +$0 | ||||
| NIH Management Fund | -0 | +||||
| + NIH Management Fund/SSF Assessment + | +$0 | ||||
| Subtotal, RMS | -$38,438,222 | +||||
| + Subtotal, RMS + | ++ $43,601,926 + | ||||
| Total DCCPS | -- | $131,165,654 | +|||
| + Total DCCPS + | ++ | + $157,821,619 + |
| Type of Mechanism | -Mechanism | -Amount | +|
|---|---|---|---|
| Type of Mechanism | +Mechanism | +Amount | |
| Centers & SPOREs | -Cancer Centers Grants-P20/P30 | -$0 | -|
| SPOREs-P50 | -0 | +||
| + Centers & SPOREs + | +Cancer Centers Grants-P20/P30 | +$0 | |
| Other P50s/P20s | -0 | +||
| SPOREs-P50 | +$0 | ||
| Other Specialized Centers | -7,149,238 | +||
| Other P50s/P20s | +$0 | ||
| Subtotal, Centers | -$7,149,238 | +||
| Other Specialized Centers | +$10,199,405 | ||
| Other Research–Grants | -Cancer Education Program-R25 (including BD2K) | -0 | +|
| + Subtotal, Centers + | ++ $10,199,405 + | ||
| Clinical Cooperative Groups-U10/UG1 | -129,370,923 | +||
| + Other Research–Grants + | ++ Cancer Education Program-R25 (including BD2K) + | +$0 | |
| PreDoc PostDoc Transition Awards-F99 | -0 | +Education Projects- UE5 | +$0 | +
| + Clinical Cooperative Groups-U10/UG1 + | +$153,530,193 | ||
| UE5 Education Projects | -0 | ++ PreDoc PostDoc Transition Awards-F99 + | +$0 |
| Minority Biomedical Support-S06 | -0 | +||
| + Minority Biomedical Support-S06 + | +$0 | ||
| Rsrch pathway in Residency-R38 | -0 | +Rsrch pathway in Residency-R38 | +$0 |
| Pilot Research Project-OT2 | -0 | +Pilot Research Project-OT2 | +$0 |
| Resource Grants-R24/U24/U2C | -0 | +||
| Resource Grants-R24/U24/U2C | +$0 | ||
| Cooperative Conference Agreements-U13/R13 | -0 | +||
| + Cooperative Conference Agreements-U13/R13 + | +$0 | ||
| Int'l Research Training Grants-D43/U2R | -0 | +||
| + International Research Training Grants-D43/U2R + | +$0 | ||
| Subtotal, Other Research Grants | -$129,370,923 | +||
| + Subtotal, Other Research Grants + | ++ $153,530,193 + | ||
| Subtotal, Research Grants | -- | $136,520,161 | +|
| + Subtotal, Research Grants + | ++ | + $163,729,598 + | |
| R&D Contracts | -R&D Contracts | -58,434,011 | +|
| + R&D Contracts + | +R&D Contracts | +$42,914,835 | |
| SBIR Contracts | -0 | +||
| SBIR Contracts | +$0 | ||
| NIH Management Fund/SSF Assessment | -0 | ++ NIH Management Fund/SSF Assessment + | +$0 |
| Subtotal, Contracts | -$58,434,011 | +||
| + Subtotal, Contracts + | ++ $42,914,835 + | ||
| Research Management & Support (RMS) | -RMS | -28,262,064 | +|
| + Research Management & Support (RMS) + | +RMS | +$30,588,221 | |
| SBIR RMS | -0 | +||
| SBIR RMS | +$0 | ||
| NIH Management Fund/SSF Assessment | -0 | +||
| + NIH Management Fund/SSF Assessment + | +$0 | ||
| Subtotal, RMS | -$28,262,064 | +||
| + Subtotal, RMS + | ++ $30,588,221 + | ||
| Total DCP | -- | $223,216,237 | +|
| + Total DCP + | ++ | + $237,232,654 + |
| Type of Mechanism | -Mechanism | -Amount | +
|---|---|---|
| Type of Mechanism | +Mechanism | +Amount |
| Research Management & Support (RMS) | -RMS | -$19,737,071 | +
| + Research Management & Support (RMS) + | +RMS | +$23,102,950 |
| SBIR RMS | -0 | +|
| SBIR RMS | +$0 | |
| NIH Management Fund | -0 | +|
| + NIH Management Fund/SSF Assessment + | +$0 | |
| Total DEA | -$19,737,071 | +|
| + Total DEA + | ++ $23,102,950 + |
| Type of Mechanism | -Mechanism | -Amount | +||
|---|---|---|---|---|
| Type of Mechanism | +Mechanism | +Amount | ||
| Research Project Grants (RPGs) | -Non-Competing | -$0 | -||
| Administrative Supplements | -0 | -|||
| Competing | -0 | -|||
| Subtotal, without SBIR/STTR Grants | -$0 | +|||
| + Research Project Grants (RPGs) + | +Non-Competing | +$0 | +||
| Administrative Supplements | +$0 | +|||
| Competing | +$0 | +|||
| + Subtotal, without SBIR/STTR Grants + | ++ $0 + | +|||
| SBIR/STTR Grants-R41 -44 | +$158,454,446 | |||
| SBIR/STTR Grants-R41 -44 | -158,269,499 | +|||
| + Subtotal, RPGs + | ++ $158,454,446 + | +|||
| + Centers & SPOREs + | +Cancer Centers Grants-P20/P30 | +$352,357,375 | +||
| SPOREs | +$486,208 | +|||
| Other P50s/P20s | +$383,091 | +|||
| Other Specialized Centers | +$58,253,447 | +|||
| + Subtotal, Centers + | ++ $411,480,121 + | +|||
| + Other Research–Career Program + | +Career Program | +$0 | +||
| Post-Doc-Fellow Awards-K00 | +$8,594,008 | +|||
| + Research Scientist Development Award-K01 + | +$4,894,207 | |||
| Subtotal, RPGs | -$158,269,499 | +|||
| Research Scientist Award-K05 | +$0 | |||
| Centers & SPOREs | -Cancer Centers Grants-P20/P30 | -344,697,904 | +||
| Academic/Teacher Award-K07 | +$0 | |||
| SPOREs | -9,357,386 | +|||
| Clinical Investigator-K08 | +$62,528,453 | |||
| Other P50s/P20s | -205,155 | +|||
| + Physician Scientist Award (Program)-K12 + | +$16,772,145 | |||
| Other Specialized Centers | -50,569,123 | +|||
| + Transitional Career Development-K22 + | +$10,175,821 | |||
| Subtotal, Centers | -$404,829,568 | +|||
| + Mentored Patient Oriented RCDA-K23 + | +$0 | |||
| Other Research–Career Program | -Career Program | -0 | +||
| + Mid-Career Invest. & Patient Orient. Res-K24 + | +$0 | |||
| Post-Doc-Fellow Awards-K00 | -7,211,442 | +|||
| Mentored Quant. Res Career-K25 | +$532,509 | |||
| Temin & Minority Mentored Awards-K01 | -5,573,009 | +|||
| + Early Stage Mentored Research and Career Development-K38 + | +$204,439 | |||
| Estab. Inv. Award-K05 | -0 | +|||
| + International Research Career Development Award-K43 + | +$402,742 | |||
| Preventive Oncology-K07 | -4,964,775 | +|||
| Career Transition Award-K99 | +$10,590,692 | |||
| Clinical Investigator-K08 | -48,478,974 | +|||
| + Subtotal, Career Program + | ++ $114,695,016 + | |||
| Clinical Oncology-K12 | -14,506,693 | -|||
| Transitional Career Development-K22 | -9,722,676 | -|||
| Mentored Patient Oriented RCDA-K23 | -534,675 | -|||
| Mid-Career Invest. & Patient Orient. Res-K24 | -354,197 | -|||
| Mentored Quant. Res Career-K25 | -157,167 | -|||
| Mentored Career Devel/Tem Intl Career-K43 | -551,375 | -|||
| Pathway Award-K99 | -10,600,361 | -|||
| Subtotal, Career Program | -$102,655,344 | -|||
| Other Research–Grants | -Cancer Education Program-R25 (including BD2K) | -17,632,838 | -||
| Clinical Cooperative Groups-U10/UG1 | -8,930,714 | -|||
| PreDoc PostDoc Transition Awards-F99 | -1,770,090 | +|||
| + Other Research–Grants + | ++ Cancer Education Program-R25 (including BD2K) + | +$23,600,697 | ||
| Education Projects-UE5 | -2,045,516 | -|||
| Minority Biomedical Support-S06 | -1,497,039 | -|||
| Rsrch Pathway in Residency-R38 | -608,718 | -|||
| Other Transaction Authority-OT2 | -3,308,166 | -|||
| Resource Grants-R24/U24/U2C | -124,161,395 | -|||
| Cooperative Conference Agreements-U13/R13 | -434,014 | -|||
| Int'l Research Training Grants-D43/U2R | -1,871,152 | -|||
| Subtotal, Other Research–Grants | -$162,259,642 | -|||
| Subtotal, Research Grants | -- | $828,014,053 | +Education Projects-UE5 | +$0 | +
| + Clinical Cooperative Groups-U10/UG1 + | +$7,270,234 | +|||
| + PreDoc PostDoc Transition Awards-F99 + | +$0 | +|||
| + Minority Biomedical Support-S06 + | +$0 | +|||
| Rsrch Pathway in Residency-R38 | +$0 | +|||
| Pilot Research Project-OT2 | +$0 | +|||
| Resource Grants-R24/U24/U2C | +$0 | +|||
| + Cooperative Conference Agreements-U13/R13 + | +$0 | +|||
| + Internationall Research Training Grants-D43/U2R + | +$0 | +|||
| + Subtotal, Other Research–Grants + | ++ $30,870,931 + | +|||
| + Subtotal, Research Grants + | ++ | + $715,500,514 + | +||
| + NRSA Fellowships + | ++ | + $87,791,141 + | +||
| + R&D Contracts + | +R&D Contracts | +$310,971,538 | +||
| SBIR Contracts | +$33,124,877 | |||
| NRSA Fellowships | -- | 92,995,313 | +||
| + NIH Management Fund/SSF Assessment + | +$0 | |||
| R&D Contracts | -R&D Contracts | -298,969,769 | +||
| + Subtotal, Contracts + | ++ $344,096,415 + | |||
| SBIR Contracts | -20,916,852 | +|||
| + Intramural Research + | +Program | +$299,299,520 | ||
| NIH Management Fund/SSF Assessment/Program Evaluation | -0 | +|||
| + NIH Management Fund/SSF Assessment + | +$0 | |||
| Subtotal, Contracts | -$319,886,621 | +|||
| + Subtotal, Intramural Research + | ++ $299,299,520 + | |||
| Intramural Research | -Program | -242,235,410 | -||
| NIH Management Fund/SSF Assessment/Program Evaluation | -0 | -|||
| Subtotal, Intramural Research | -$242,235,410 | -|||
| Research Management & Support (RMS) | -RMS | -189,930,914 | +||
| + Research Management & Support (RMS) + | +RMS | +$219,542,648 | ||
| SBIR RMS | -3,056,688 | +|||
| SBIR RMS | +$4,487,150 | |||
| NIH Management Fund/SSF Assessment/Program Evaluation | -0 | +|||
| + NIH Management Fund/SSF Assessment + | +$0 | |||
| Subtotal, RMS | -$192,987,602 | +|||
| + Subtotal, RMS + | ++ $224,029,798 + | |||
| Buildings and Facilities | -- | 30,000,000 | +||
| + Buildings and Facilities + | ++ | $30,000,000 | ||
| Total OD | -- | $1,706,118,998 | +||
| + Total OD + | ++ | + $1,700,717,388 + |
Each fiscal year, NCI and other NIH institutes and centers report their obligations by mechanism. In addition to reporting by mechanism, reporting obligations by program structure is another way of showing how NCI obligates its funding each fiscal year.
- -For the purposes of reporting by program structure, NCI programs are categorized by budget activity. These budget activities include:
- ++ Each fiscal year, NCI and other NIH Institutes and Centers report their + obligations by mechanism. In addition to reporting by mechanism, reporting + obligations by program structure is another way of showing how NCI obligates + its funding each fiscal year. +
++ For the purposes of reporting by program structure, NCI programs are + categorized by budget activity. These budget activities include: +
- -
Includes FY 2021 Cures Moonshot funding and excludes FYs 2019 through 2020 Cures Moonshot carryover obligations.
- ## Extramural vs Intramural and RMS Funding -- entity: "block_content" - type: "raw_html_block" - info: "Factbook-rms-funding" +- entity: 'block_content' + type: 'raw_html_block' + info: 'Factbook-rms-funding' info__ES: value: langcode: en status: 1 field_raw_html: - - format: "raw_html" + - format: 'raw_html' value: | - + field_raw_html__ES: - - format: "raw_html" + - format: 'raw_html' value: -- entity: "node" - type: "cgov_article" +- entity: 'node' + type: 'cgov_article' langcode: en status: 1 moderation_state: value: 'published' - title: "Extramural vs Intramural and RMS Funding" + title: 'Extramural vs Intramural and RMS Funding' field_browser_title: - value: "2021 NCI Budget Fact Book - Extramural vs Intramural Funding" + value: '2021 NCI Budget Fact Book - Extramural vs Intramural Funding' field_page_description: - value: "See a comparison of extramural funding and intramural and research management funding by mechanism since 2015." + value: 'See a comparison of extramural funding and intramural and research management funding by mechanism since 2015.' field_card_title: - value: "Extramural vs Intramural & RMS Funding" + value: 'Extramural vs Intramural & RMS Funding' field_card_description: - value: "See a comparison of extramural and intramural funding by mechanism since 2014." + value: 'See a comparison of extramural and intramural funding by mechanism since 2014.' field_site_section: - '#process': callback: 'reference' @@ -3962,230 +6105,419 @@ computed_path: '/about-nci/budget/fact-book/historical-trends/extramural-intramural-rms' field_article_body: - entity: 'paragraph' - type: "body_section" + type: 'body_section' field_body_section_content: - - format: "ncids_full_html" + - format: 'ncids_full_html' value: | -The following is a comparison broken out by mechanism and total between Extramural dollars spent vs Intramural Research Program (IRP) and Research Management and Support (RMS).
++ The following is a comparison broken out by mechanism and total between + Extramural dollars spent vs Intramural Research Program (IRP) and Research + Management and Support (RMS). +
- +- -
*Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.
-| 2017* | -2018* | -2019* | -2020* | -2021* | -2017-2021 % Change | +|||
|---|---|---|---|---|---|---|---|---|
| 2017* | +2018* | +2019* | +2020* | +2021* | +2022* | +2023* | +2024 | +2017-2024 % Change |
| $5,636.4 | -$5,927.7 | -$5,992.3 | -$6,383.4 | -$6,442.7 | -14.3% | +|||
| + $5,636.4 + | ++ $5,927.7 + | ++ $5,992.3 + | ++ $6,383.4 + | ++ $6,442.7 + | ++ $6,833.7 + | ++ $7,186.8 + | ++ $7,240.9 + | ++ 0.8% + |
| *Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021. | +||||||||
| + *Fiscal years 2023 through 2017 include Cancer MoonshotSM + funding appropriated that fiscal year and exclude all carryover + obligations for fiscal years 2023 through 2018. + | ||||||||
| Mechanism | -2017* | -2018* | -2019* | -2020* | -2021* | -2017-2021 % Change | +|||
|---|---|---|---|---|---|---|---|---|---|
| Mechanism | +2017* | +2018* | +2019* | +2020* | +2021* | +2022* | +2023* | +2024 | +2017-2024 % Change |
| Research Project Grants | -$2,278.4 | -$2,450.6 | -$2,541.7 | -$2,749.4 | -$2,822.4 | -23.9% | -|||
| Cancer Centers | -313.0 | -331.4 | -337.1 | -382.0 | -344.7 | -10.1% | -|||
| SPOREs | -111.4 | -115.8 | -110.7 | -113.2 | -119.6 | -7.3% | -|||
| Other P50s/P20s | -1.3 | -0.0 | -7.4 | -7.9 | -3.3 | -147.0% | -|||
| Other Specialized Centers | -135.6 | -178.3 | -200.8 | -110.7 | -95.9 | --29.2% | -|||
| Other Research Grants | -481.9 | -537.9 | -506.8 | -548.1 | -556.2 | -15.4% | -|||
| NRSA | -77.6 | -82.4 | -87.0 | -96.4 | -93.0 | -19.8% | -|||
| R&D Contract | -880.4 | -825.4 | -768.1 | -823.0 | -812.2 | --7.7% | -|||
| Buildings & Facilities | -30.0 | -18.0 | -18.0 | -30.0 | -30.0 | -0.0% | -|||
| Total Extramural Funds | -$4,309.7 | -$4,539.8 | -$4,577.5 | -$4,860.7 | -$4,877.3 | -13.2% | -|||
| *Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021. | +|||||||||
| Research Project Grants | +$2,278.4 | +$2,450.6 | +$2,541.7 | +$2,749.4 | +$2,822.4 | +$2,966.5 | +$3,145.2 | +$3,129.8 | +-0.5% | +
| Cancer Centers | +313.0 | +331.4 | +337.1 | +382.0 | +344.7 | +339.7 | +353.5 | +495.1 | +40.1% | +
| SPOREs | +111.4 | +115.8 | +110.7 | +113.2 | +119.6 | +128.2 | +124.1 | +113.9 | +-8.2% | +
| Other P50s/P20s | +1.3 | +0.0 | +7.4 | +7.9 | +3.3 | +13.2 | +5.3 | +5.3 | +0.0% | +
| Other Specialized Centers | +135.6 | +178.3 | +200.8 | +110.7 | +95.9 | +106.0 | +141.5 | +137.6 | +-2.8% | +
| Other Research Grants | +481.9 | +537.9 | +506.8 | +548.1 | +556.2 | +624.8 | +621.5 | +606.4 | +-2.4% | +
| NRSA | +77.6 | +82.4 | +87.0 | +96.4 | +93.0 | +91.1 | +90.3 | +89.9 | +-0.4% | +
| R&D Contracts | +880.4 | +825.4 | +768.1 | +823.0 | +812.2 | +835.8 | +899.1 | +888.2 | +-1.2% | +
| Buildings & Facilities | +30.0 | +18.0 | +18.0 | +30.0 | +30.0 | +30.0 | +30.0 | +30.0 | +0.0% | +
| + Total Extramural Funds + | ++ $4,309.7 + | ++ $4,539.8 + | ++ $4,577.5 + | ++ $4,860.7 + | ++ $4,877.3 + | ++ $5,135.3 + | ++ $5,410.5 + | ++ $5,496.2 + | ++ 1.6% + | +
| + *Fiscal years 2023 through 2017 include Cancer MoonshotSM + funding appropriated that fiscal year and exclude all carryover + obligations for fiscal years 2023 through 2018. + | |||||||||
| Mechanism | -2017* | -2018* | -2019* | -2020* | -2021* | -2017-2021 % Change | +|||
|---|---|---|---|---|---|---|---|---|---|
| + Mechanism + | ++ 2017* + | ++ 2018* + | ++ 2019* + | ++ 2020* + | ++ 2021* + | ++ 2022* + | ++ 2023* + | ++ 2024 + | ++ 2017-2024 % Change + |
| Intramural Research | -$899.7 | -$945.5 | -$964.9 | -$1,072.6 | -$1,102.5 | -22.5% | -|||
| RMS | -427.0 | -442.4 | -449.9 | -450.0 | -462.9 | -8.4% | -|||
| Total IRP & RMS Funds | -$1,326.7 | -$1,387.9 | -$1,414.8 | -$1,522.6 | -$1,565.4 | -18.0% | -|||
| *Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021. | +|||||||||
| Intramural Research | +$899.7 | +$945.5 | +$964.9 | +$1,072.6 | +$1,102.5 | +$1,230.4 | +$1,278.5 | +$1,345.4 | +5.2% | +
| RMS | +427.0 | +442.4 | +449.9 | +450.0 | +462.9 | +468.0 | +497.8 | +399.3 | +-19.8% | +
| + Total IRP & RMS Funds + | ++ $1,326.7 + | ++ $1,387.9 + | ++ $1,414.8 + | ++ $1,522.6 + | ++ $1,565.4 + | ++ $1,698.4 + | ++ $1,776.3 + | ++ $1,744.7 + | ++ -1.8% + | +
| + *Fiscal years 2023 through 2017 include Cancer MoonshotSM + funding appropriated that fiscal year and exclude all carryover + obligations for fiscal years 2023 through 2018. + | |||||||||